
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml"
      xmlns:dc="http://purl.org/dc/terms/"
      xmlns:doi="http://dx.doi.org/"
      lang="en" xml:lang="en"
      itemscope itemtype="http://schema.org/Article"
      class="no-js">



<head prefix="og: http://ogp.me/ns#">
  <title>Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis</title>







<link rel="stylesheet" href="/plosone/resource/compiled/asset_V7OLX4LSII2Y4DADFWUTOT572TJ6EECJ.css" />

  <!-- allows for  extra head tags -->


<!-- hello -->
<link rel="stylesheet" type="text/css"
      href="https://fonts.googleapis.com/css?family=Open+Sans:400,400i,600">

<link media="print" rel="stylesheet" type="text/css"  href="/plosone/resource/css/print.css"/>
    <script type="text/javascript">
        var siteUrlPrefix = "/plosone/";
    </script>
<script src="/plosone/resource/compiled/asset_SC5JIUGEUPR4P4P6VBUINUVOVUSU3NRY.js"></script>

  <link rel="shortcut icon" href="/plosone/resource/img/favicon.ico" type="image/x-icon"/>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>






  <link rel="canonical" href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0100206" />
  <meta name="description" content="Background Recent genomic sequencing efforts have identified a number of recurrent mutations in myelodysplastic syndromes (MDS) that may contribute to disease progression and overall survival, including mutations in isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2).  Methods Pretreatment bone marrow (BM) samples were acquired from mononuclear cells in 146 adult patients with de novo MDS from January 2006 to June 2013. Polymerase chain reaction (PCR) and direct sequencing were performed on exon 4 of IDH1/2 genes and mutation status was correlated with overall survival (OS) and leukemia-free survival (LFS). We then performed a meta-analysis combining previously published and current studies to explore the effect of IDH mutations on OS and LFS in MDS.  Results In our study, somatic mutations of either IDH gene were discovered in 11 MDS patients (7.53%) and were significantly correlated with poorer OS (P = 0.007). IDH mutations were specifically associated with a poorer OS in the intermediate-1 risk group by the International Prognostic Scoring System (IPSS) (P = 0.039). In addition, we discovered decitabine achieved a better therapeutic effect compared to other treatments in IDH mutation-positive patients (P = 0.023). We identified six previous studies of IDH mutations in MDS. A meta-analysis of these studies included 111 MDS patients IDH mutations and 1671 MDS patients with wild-type IDH1/2. The hazard ratios (HRs) of OS and LFS for patients with IDH mutations were 1.62 (95% CI, 1.27&ndash;2.09) and 2.21 (95% CI, 1.48&ndash;3.30), respectively.  Conclusion The results from our study and the meta-analysis provide firm evidence that IDH mutations are significantly associated with poorer clinical outcomes in MDS. Identification of IDH mutations may be pivotal for better risk stratification in MDS patients and improving IPSS score. Additionally, hypomethylating agents may be an effective treatment option for MDS patients with IDH mutations." />

  <meta name="keywords" content="Meta-analysis,Prognosis,Mutation detection,Karyotypes,Cancer treatment,Cytogenetics,Mutation,Myelodysplastic syndromes" />


<meta name="citation_doi" content="10.1371/journal.pone.0100206"/>
<meta name="citation_author" content="Jie Jin"/>
  <meta name="citation_author_institution" content="Department of Hematology, the First Affiliated Hospital of Zhejiang University, Hangzhou, People’s Republic of China"/>
  <meta name="citation_author_institution" content="Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China"/>
<meta name="citation_author" content="Chao Hu"/>
  <meta name="citation_author_institution" content="Department of Hematology, the First Affiliated Hospital of Zhejiang University, Hangzhou, People’s Republic of China"/>
  <meta name="citation_author_institution" content="Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China"/>
<meta name="citation_author" content="Mengxia Yu"/>
  <meta name="citation_author_institution" content="Department of Hematology, the First Affiliated Hospital of Zhejiang University, Hangzhou, People’s Republic of China"/>
  <meta name="citation_author_institution" content="Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China"/>
<meta name="citation_author" content="Feifei Chen"/>
  <meta name="citation_author_institution" content="Department of Hematology, the First Affiliated Hospital of Zhejiang University, Hangzhou, People’s Republic of China"/>
  <meta name="citation_author_institution" content="Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China"/>
<meta name="citation_author" content="Li Ye"/>
  <meta name="citation_author_institution" content="Department of Hematology, the First Affiliated Hospital of Zhejiang University, Hangzhou, People’s Republic of China"/>
  <meta name="citation_author_institution" content="Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China"/>
<meta name="citation_author" content="Xiufeng Yin"/>
  <meta name="citation_author_institution" content="Department of Hematology, the First Affiliated Hospital of Zhejiang University, Hangzhou, People’s Republic of China"/>
  <meta name="citation_author_institution" content="Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China"/>
<meta name="citation_author" content="Zhengping Zhuang"/>
  <meta name="citation_author_institution" content="Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America"/>
<meta name="citation_author" content="Hongyan Tong"/>
  <meta name="citation_author_institution" content="Department of Hematology, the First Affiliated Hospital of Zhejiang University, Hangzhou, People’s Republic of China"/>
  <meta name="citation_author_institution" content="Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China"/>

<meta name="citation_title" content="Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis"/>
<meta itemprop="name" content="Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis"/>
<meta name="citation_journal_title" content="PLOS ONE"/>
<meta name="citation_journal_abbrev" content="PLOS ONE"/>
<meta name="citation_date" content="Jun 17, 2014"/>
<meta name="citation_firstpage" content="e100206"/>
<meta name="citation_issue" content="6"/>
<meta name="citation_volume" content="9"/>
<meta name="citation_issn" content="1932-6203"/>
<meta name="citation_publisher" content="Public Library of Science"/>

  <meta name="citation_pdf_url" content="http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0100206&type=printable">


<meta name="dc.identifier" content="10.1371/journal.pone.0100206" />


  <meta name="twitter:card" content="summary" />
  <meta name="twitter:site" content="@plosone"/>
    <meta name="twitter:title" content="Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis" />
    <meta property="twitter:description" content="Background Recent genomic sequencing efforts have identified a number of recurrent mutations in myelodysplastic syndromes (MDS) that may contribute to disease progression and overall survival, including mutations in isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2).  Methods Pretreatment bone marrow (BM) samples were acquired from mononuclear cells in 146 adult patients with de novo MDS from January 2006 to June 2013. Polymerase chain reaction (PCR) and direct sequencing were performed on exon 4 of IDH1/2 genes and mutation status was correlated with overall survival (OS) and leukemia-free survival (LFS). We then performed a meta-analysis combining previously published and current studies to explore the effect of IDH mutations on OS and LFS in MDS.  Results In our study, somatic mutations of either IDH gene were discovered in 11 MDS patients (7.53%) and were significantly correlated with poorer OS (P = 0.007). IDH mutations were specifically associated with a poorer OS in the intermediate-1 risk group by the International Prognostic Scoring System (IPSS) (P = 0.039). In addition, we discovered decitabine achieved a better therapeutic effect compared to other treatments in IDH mutation-positive patients (P = 0.023). We identified six previous studies of IDH mutations in MDS. A meta-analysis of these studies included 111 MDS patients IDH mutations and 1671 MDS patients with wild-type IDH1/2. The hazard ratios (HRs) of OS and LFS for patients with IDH mutations were 1.62 (95% CI, 1.27&ndash;2.09) and 2.21 (95% CI, 1.48&ndash;3.30), respectively.  Conclusion The results from our study and the meta-analysis provide firm evidence that IDH mutations are significantly associated with poorer clinical outcomes in MDS. Identification of IDH mutations may be pivotal for better risk stratification in MDS patients and improving IPSS score. Additionally, hypomethylating agents may be an effective treatment option for MDS patients with IDH mutations." />
    <meta property="twitter:image" content="http://journals.plos.org/plosone/article/figure/image?id=10.1371/journal.pone.0100206.g004&size=inline" />

<meta property="og:type" content="article" />
<meta property="og:url" content="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0100206"/>
<meta property="og:title" content="Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis"/>
<meta property="og:description" content="Background Recent genomic sequencing efforts have identified a number of recurrent mutations in myelodysplastic syndromes (MDS) that may contribute to disease progression and overall survival, including mutations in isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2).  Methods Pretreatment bone marrow (BM) samples were acquired from mononuclear cells in 146 adult patients with de novo MDS from January 2006 to June 2013. Polymerase chain reaction (PCR) and direct sequencing were performed on exon 4 of IDH1/2 genes and mutation status was correlated with overall survival (OS) and leukemia-free survival (LFS). We then performed a meta-analysis combining previously published and current studies to explore the effect of IDH mutations on OS and LFS in MDS.  Results In our study, somatic mutations of either IDH gene were discovered in 11 MDS patients (7.53%) and were significantly correlated with poorer OS (P = 0.007). IDH mutations were specifically associated with a poorer OS in the intermediate-1 risk group by the International Prognostic Scoring System (IPSS) (P = 0.039). In addition, we discovered decitabine achieved a better therapeutic effect compared to other treatments in IDH mutation-positive patients (P = 0.023). We identified six previous studies of IDH mutations in MDS. A meta-analysis of these studies included 111 MDS patients IDH mutations and 1671 MDS patients with wild-type IDH1/2. The hazard ratios (HRs) of OS and LFS for patients with IDH mutations were 1.62 (95% CI, 1.27&ndash;2.09) and 2.21 (95% CI, 1.48&ndash;3.30), respectively.  Conclusion The results from our study and the meta-analysis provide firm evidence that IDH mutations are significantly associated with poorer clinical outcomes in MDS. Identification of IDH mutations may be pivotal for better risk stratification in MDS patients and improving IPSS score. Additionally, hypomethylating agents may be an effective treatment option for MDS patients with IDH mutations."/>
<meta property="og:image" content="http://journals.plos.org/plosone/article/figure/image?id=10.1371/journal.pone.0100206.g004&size=inline"/>

<meta name="citation_reference" content="citation_title=Myelodysplastic syndromes: the complexity of stem-cell diseases;citation_author=SJ Corey;citation_author=MD Minden;citation_author=DL Barber;citation_author=H Kantarjian;citation_author=JC Wang;citation_journal_title=Nat Rev Cancer;citation_volume=7;citation_number=7;citation_first_page=118;citation_last_page=129;citation_publication_date=2007;"/>    
<meta name="citation_reference" content="citation_title=Myelodysplastic syndromes;citation_author=SD Nimer;citation_journal_title=Blood;citation_volume=111;citation_number=111;citation_first_page=4841;citation_last_page=4851;citation_publication_date=2008;"/>    
<meta name="citation_reference" content="citation_title=Clinical effect of point mutations in myelodysplastic syndromes;citation_author=R Bejar;citation_author=K Stevenson;citation_author=O Abdel-Wahab;citation_author=N Galili;citation_author=B Nilsson;citation_journal_title=N Engl J Med;citation_volume=364;citation_number=364;citation_first_page=2496;citation_last_page=2506;citation_publication_date=2011;"/>    
<meta name="citation_reference" content="citation_title=International scoring system for evaluating prognosis in myelodysplastic syndromes;citation_author=P Greenberg;citation_author=C Cox;citation_author=MM LeBeau;citation_author=P Fenaux;citation_author=P Morel;citation_journal_title=Blood;citation_volume=89;citation_number=89;citation_first_page=2079;citation_last_page=2088;citation_publication_date=1997;"/>    
<meta name="citation_reference" content="citation_title=Revised international prognostic scoring system for myelodysplastic syndromes;citation_author=PL Greenberg;citation_author=H Tuechler;citation_author=J Schanz;citation_author=G Sanz;citation_author=G Garcia-Manero;citation_journal_title=Blood;citation_volume=120;citation_number=120;citation_first_page=2454;citation_last_page=2465;citation_publication_date=2012;"/>    
<meta name="citation_reference" content="citation_title=Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes;citation_author=L Malcovati;citation_author=U Germing;citation_author=A Kuendgen;citation_author=MG Della Porta;citation_author=C Pascutto;citation_journal_title=J Clin Oncol;citation_volume=25;citation_number=25;citation_first_page=3503;citation_last_page=3510;citation_publication_date=2007;"/>    
<meta name="citation_reference" content="citation_title=Unraveling the molecular pathophysiology of myelodysplastic syndromes;citation_author=R Bejar;citation_author=R Levine;citation_author=BL Ebert;citation_journal_title=J Clin Oncol;citation_volume=29;citation_number=29;citation_first_page=504;citation_last_page=515;citation_publication_date=2011;"/>    
<meta name="citation_reference" content="citation_title=Molecular biology of myelodysplastic syndromes;citation_author=AH Shih;citation_author=RL Levine;citation_journal_title=Semin Oncol;citation_volume=38;citation_number=38;citation_first_page=613;citation_last_page=620;citation_publication_date=2011;"/>    
<meta name="citation_reference" content="citation_title=A prognostic score for patients with lower risk myelodysplastic syndrome;citation_author=G Garcia-Manero;citation_author=J Shan;citation_author=S Faderl;citation_author=J Cortes;citation_author=F Ravandi;citation_journal_title=Leukemia;citation_volume=22;citation_number=22;citation_first_page=538;citation_last_page=543;citation_publication_date=2008;"/>    
<meta name="citation_reference" content="citation_title=Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism;citation_author=ZJ Reitman;citation_author=H Yan;citation_journal_title=J Natl Cancer Inst;citation_volume=102;citation_number=102;citation_first_page=932;citation_last_page=941;citation_publication_date=2010;"/>    
<meta name="citation_reference" content="citation_title=Epigenetic alterations in hematopoietic malignancies;citation_author=YR Chung;citation_author=E Schatoff;citation_author=O Abdel-Wahab;citation_journal_title=Int J Hematol;citation_volume=96;citation_number=96;citation_first_page=413;citation_last_page=427;citation_publication_date=2012;"/>    
<meta name="citation_reference" content="citation_title=Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases;citation_author=WG Kaelin Jr;citation_journal_title=Cold Spring Harb Symp Quant Biol;citation_volume=76;citation_number=76;citation_first_page=335;citation_last_page=345;citation_publication_date=2011;"/>    
<meta name="citation_reference" content="citation_title=The World Health Organization (WHO) classification of the myeloid neoplasms;citation_author=JW Vardiman;citation_author=NL Harris;citation_author=RD Brunning;citation_journal_title=Blood;citation_volume=100;citation_number=100;citation_first_page=2292;citation_last_page=2302;citation_publication_date=2002;"/>    
<meta name="citation_reference" content="citation_title=Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients;citation_author=MM Patnaik;citation_author=CA Hanson;citation_author=JM Hodnefield;citation_author=TL Lasho;citation_author=CM Finke;citation_journal_title=Leukemia;citation_volume=26;citation_number=26;citation_first_page=101;citation_last_page=105;citation_publication_date=2012;"/>    
<meta name="citation_reference" content="citation_title=IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis;citation_author=F Thol;citation_author=EM Weissinger;citation_author=J Krauter;citation_author=K Wagner;citation_author=F Damm;citation_journal_title=Haematologica;citation_volume=95;citation_number=95;citation_first_page=1668;citation_last_page=1674;citation_publication_date=2010;"/>    
<meta name="citation_reference" content="citation_title=IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome;citation_author=J Lin;citation_author=DM Yao;citation_author=J Qian;citation_author=Q Chen;citation_author=W Qian;citation_journal_title=Ann Hematol;citation_volume=91;citation_number=91;citation_first_page=519;citation_last_page=525;citation_publication_date=2012;"/>    
<meta name="citation_reference" content="citation_title=Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations;citation_author=TL Lin;citation_author=Y Nagata;citation_author=HW Kao;citation_author=M Sanada;citation_author=Y Okuno;citation_journal_title=Haematologica;citation_publication_date=2013;"/>    
<meta name="citation_reference" content="citation_title=IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution;citation_author=CC Lin;citation_author=HA Hou;citation_author=WC Chou;citation_author=YY Kuo;citation_author=CY Liu;citation_journal_title=Am J Hematol;citation_publication_date=2013;"/>    
<meta name="citation_reference" content="citation_title=Practical methods for incorporating summary time-to-event data into meta-analysis;citation_author=JF Tierney;citation_author=LA Stewart;citation_author=D Ghersi;citation_author=S Burdett;citation_author=MR Sydes;citation_journal_title=Trials;citation_volume=8;citation_number=8;citation_first_page=16;citation_publication_date=2007;"/>    
<meta name="citation_reference" content="citation_title=A Meta-Analysis of the Relationship between Cigarette Smoking and Incidence of Myelodysplastic Syndromes;citation_author=H Tong;citation_author=C Hu;citation_author=X Yin;citation_author=M Yu;citation_author=J Yang;citation_journal_title=PLoS One;citation_volume=8;citation_number=8;citation_first_page=e67537;citation_publication_date=2013;"/>    
<meta name="citation_reference" content="citation_title=Operating characteristics of a rank correlation test for publication bias;citation_author=CB Begg;citation_author=M Mazumdar;citation_journal_title=Biometrics;citation_volume=50;citation_number=50;citation_first_page=1088;citation_last_page=1101;citation_publication_date=1994;"/>    
<meta name="citation_reference" content="citation_title=Bias in meta-analysis detected by a simple, graphical test;citation_author=M Egger;citation_author=G Davey Smith;citation_author=M Schneider;citation_author=C Minder;citation_journal_title=BMJ;citation_volume=315;citation_number=315;citation_first_page=629;citation_last_page=634;citation_publication_date=1997;"/>    
<meta name="citation_reference" content="citation_title=World Health Organization classification of the acute leukemias and myelodysplastic syndrome;citation_author=JM Bennett;citation_journal_title=Int J Hematol;citation_volume=72;citation_number=72;citation_first_page=131;citation_last_page=133;citation_publication_date=2000;"/>    
<meta name="citation_reference" content="citation_title=Proposals for the classification of the myelodysplastic syndromes;citation_author=JM Bennett;citation_author=D Catovsky;citation_author=MT Daniel;citation_author=G Flandrin;citation_author=DA Galton;citation_journal_title=Br J Haematol;citation_volume=51;citation_number=51;citation_first_page=189;citation_last_page=199;citation_publication_date=1982;"/>    
<meta name="citation_reference" content="citation_title=New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice;citation_author=Z Tothova;citation_author=DP Steensma;citation_author=BL Ebert;citation_journal_title=Clin Cancer Res;citation_volume=19;citation_number=19;citation_first_page=1637;citation_last_page=1643;citation_publication_date=2013;"/>    
<meta name="citation_reference" content="citation_title=Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders;citation_author=T Muto;citation_author=G Sashida;citation_author=M Oshima;citation_author=GR Wendt;citation_author=M Mochizuki-Kashio;citation_journal_title=J Exp Med;citation_volume=210;citation_number=210;citation_first_page=2627;citation_last_page=2639;citation_publication_date=2013;"/>    
<meta name="citation_reference" content="citation_title=Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma;citation_author=D Krell;citation_author=M Assoku;citation_author=M Galloway;citation_author=P Mulholland;citation_author=I Tomlinson;citation_journal_title=PLoS One;citation_volume=6;citation_number=6;citation_first_page=e19868;citation_publication_date=2011;"/>    
<meta name="citation_reference" content="citation_title=2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations;citation_author=G Jin;citation_author=ZJ Reitman;citation_author=I Spasojevic;citation_author=I Batinic-Haberle;citation_author=J Yang;citation_journal_title=PLoS One;citation_volume=6;citation_number=6;citation_first_page=e16812;citation_publication_date=2011;"/>    
<meta name="citation_reference" content="citation_title=The consensus coding sequences of human breast and colorectal cancers;citation_author=T Sjoblom;citation_author=S Jones;citation_author=LD Wood;citation_author=DW Parsons;citation_author=J Lin;citation_journal_title=Science;citation_volume=314;citation_number=314;citation_first_page=268;citation_last_page=274;citation_publication_date=2006;"/>    
<meta name="citation_reference" content="citation_title=A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders;citation_author=K Yoshida;citation_author=M Sanada;citation_author=M Kato;citation_author=R Kawahata;citation_author=A Matsubara;citation_journal_title=Leukemia;citation_volume=25;citation_number=25;citation_first_page=184;citation_last_page=186;citation_publication_date=2011;"/>    
<meta name="citation_reference" content="citation_title=Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias;citation_author=J Rocquain;citation_author=N Carbuccia;citation_author=V Trouplin;citation_author=S Raynaud;citation_author=A Murati;citation_journal_title=BMC Cancer;citation_volume=10;citation_number=10;citation_first_page=401;citation_publication_date=2010;"/>    
<meta name="citation_reference" content="citation_title=Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms;citation_author=O Kosmider;citation_author=V Gelsi-Boyer;citation_author=L Slama;citation_author=F Dreyfus;citation_author=O Beyne-Rauzy;citation_journal_title=Leukemia;citation_volume=24;citation_number=24;citation_first_page=1094;citation_last_page=1096;citation_publication_date=2010;"/>    
<meta name="citation_reference" content="citation_title=Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value;citation_author=S Abbas;citation_author=S Lugthart;citation_author=FG Kavelaars;citation_author=A Schelen;citation_author=JE Koenders;citation_journal_title=Blood;citation_volume=116;citation_number=116;citation_first_page=2122;citation_last_page=2126;citation_publication_date=2010;"/>    
<meta name="citation_reference" content="citation_title=IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms;citation_author=A Pardanani;citation_author=TL Lasho;citation_author=CM Finke;citation_author=M Mai;citation_author=RF McClure;citation_journal_title=Leukemia;citation_volume=24;citation_number=24;citation_first_page=1146;citation_last_page=1151;citation_publication_date=2010;"/>    
<meta name="citation_reference" content="citation_title=IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F;citation_author=A Tefferi;citation_author=T Jimma;citation_author=NH Sulai;citation_author=TL Lasho;citation_author=CM Finke;citation_journal_title=Leukemia;citation_volume=26;citation_number=26;citation_first_page=475;citation_last_page=480;citation_publication_date=2012;"/>    
<meta name="citation_reference" content="citation_title=The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia;citation_author=WC Chou;citation_author=WC Lei;citation_author=BS Ko;citation_author=HA Hou;citation_author=CY Chen;citation_journal_title=Leukemia;citation_volume=25;citation_number=25;citation_first_page=246;citation_last_page=253;citation_publication_date=2011;"/>    
<meta name="citation_reference" content="citation_title=Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation;citation_author=WC Chou;citation_author=HA Hou;citation_author=CY Chen;citation_author=JL Tang;citation_author=M Yao;citation_journal_title=Blood;citation_volume=115;citation_number=115;citation_first_page=2749;citation_last_page=2754;citation_publication_date=2010;"/>    
<meta name="citation_reference" content="citation_title=IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia;citation_author=D Caramazza;citation_author=TL Lasho;citation_author=CM Finke;citation_author=N Gangat;citation_author=D Dingli;citation_journal_title=Leukemia;citation_volume=24;citation_number=24;citation_first_page=2120;citation_last_page=2122;citation_publication_date=2010;"/>    
<meta name="citation_reference" content="citation_title=Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response;citation_author=AT Fathi;citation_author=H Sadrzadeh;citation_author=DR Borger;citation_author=KK Ballen;citation_author=PC Amrein;citation_journal_title=Blood;citation_volume=120;citation_number=120;citation_first_page=4649;citation_last_page=4652;citation_publication_date=2012;"/>    
<meta name="citation_reference" content="citation_title=Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia;citation_author=CD Dinardo;citation_author=KJ Propert;citation_author=AW Loren;citation_author=E Paietta;citation_author=Z Sun;citation_journal_title=Blood;citation_volume=121;citation_number=121;citation_first_page=4917;citation_last_page=4924;citation_publication_date=2013;"/>    
<meta name="citation_reference" content="citation_title=Are myelodysplastic syndromes “cancer”? Unexpected adverse consequences of linguistic ambiguity;citation_author=DP Steensma;citation_journal_title=Leuk Res;citation_volume=30;citation_number=30;citation_first_page=1227;citation_last_page=1233;citation_publication_date=2006;"/>    
<meta name="citation_reference" content="citation_title=Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes;citation_author=H Khan;citation_author=C Vale;citation_author=T Bhagat;citation_author=A Verma;citation_journal_title=Semin Hematol;citation_volume=50;citation_number=50;citation_first_page=16;citation_last_page=37;citation_publication_date=2013;"/>    
<meta name="citation_reference" content="citation_title=Cancer-associated IDH1 mutations produce 2-hydroxyglutarate;citation_author=L Dang;citation_author=DW White;citation_author=S Gross;citation_author=BD Bennett;citation_author=MA Bittinger;citation_journal_title=Nature;citation_volume=462;citation_number=462;citation_first_page=739;citation_last_page=744;citation_publication_date=2009;"/>    
<meta name="citation_reference" content="citation_title=Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation;citation_author=ME Figueroa;citation_author=O Abdel-Wahab;citation_author=C Lu;citation_author=PS Ward;citation_author=J Patel;citation_journal_title=Cancer Cell;citation_volume=18;citation_number=18;citation_first_page=553;citation_last_page=567;citation_publication_date=2010;"/>    
<meta name="citation_reference" content="citation_title=The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate;citation_author=PS Ward;citation_author=J Patel;citation_author=DR Wise;citation_author=O Abdel-Wahab;citation_author=BD Bennett;citation_journal_title=Cancer Cell;citation_volume=17;citation_number=17;citation_first_page=225;citation_last_page=234;citation_publication_date=2010;"/>    
<meta name="citation_reference" content="citation_title=Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha;citation_author=S Zhao;citation_author=Y Lin;citation_author=W Xu;citation_author=W Jiang;citation_author=Z Zha;citation_journal_title=Science;citation_volume=324;citation_number=324;citation_first_page=261;citation_last_page=265;citation_publication_date=2009;"/>    
<meta name="citation_reference" content="citation_title=Hypoxia-inducible factor-1alpha expression indicates poor prognosis in myelodysplastic syndromes;citation_author=H Tong;citation_author=C Hu;citation_author=Z Zhuang;citation_author=L Wang;citation_author=J Jin;citation_journal_title=Leuk Lymphoma;citation_volume=53;citation_number=53;citation_first_page=2412;citation_last_page=2418;citation_publication_date=2012;"/>    
<meta name="citation_reference" content="citation_title=Innovative analyses support a role for DNA damage and an aberrant cell cycle in myelodysplastic syndrome pathogenesis;citation_author=DR Head;citation_author=JW Jacobberger;citation_author=C Mosse;citation_author=M Jagasia;citation_author=W Dupont;citation_journal_title=Bone Marrow Res;citation_volume=2011;citation_number=2,011;citation_first_page=950934;citation_publication_date=2011;"/>    
<meta name="citation_reference" content="citation_title=Cohort studies: marching towards outcomes;citation_author=DA Grimes;citation_author=KF Schulz;citation_journal_title=Lancet;citation_volume=359;citation_number=359;citation_first_page=341;citation_last_page=345;citation_publication_date=2002;"/>    
<meta name="citation_reference" content="citation_title=ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression;citation_author=O Abdel-Wahab;citation_author=M Adli;citation_author=LM LaFave;citation_author=J Gao;citation_author=T Hricik;citation_journal_title=Cancer Cell;citation_volume=22;citation_number=22;citation_first_page=180;citation_last_page=193;citation_publication_date=2012;"/>    


<!-- DoubleClick overall ad setup script -->
<script type='text/javascript'>
  var googletag = googletag || {};
  googletag.cmd = googletag.cmd || [];
  (function() {
    var gads = document.createElement('script');
    gads.async = true;
    gads.type = 'text/javascript';
    var useSSL = 'https:' == document.location.protocol;
    gads.src = (useSSL ? 'https:' : 'http:') +
        '//www.googletagservices.com/tag/js/gpt.js';
    var node = document.getElementsByTagName('script')[0];
    node.parentNode.insertBefore(gads, node);
  })();
</script>

<!-- DoubleClick ad slot setup script -->

  <script id="doubleClickSetupScript" type='text/javascript'>
    googletag.cmd.push(function() {
  googletag.defineSlot('/75507958/PONE_728x90_ATF', [728, 90], 'div-gpt-ad-1458247671871-0').addService(googletag.pubads());
  googletag.defineSlot('/75507958/PONE_160x600_BTF', [160, 600], 'div-gpt-ad-1458247671871-1').addService(googletag.pubads());
      googletag.pubads().enableSingleRequest();
      googletag.enableServices();
    });
  </script>



<script type="text/javascript">
    var WombatConfig = WombatConfig || {};
    WombatConfig.resourcePath = "/plosone/resource/";
    WombatConfig.imgPath = "/plosone/resource/img/";
    WombatConfig.journalKey = "PLoSONE";
    WombatConfig.figurePath = "/plosone/article/figure/image";
    WombatConfig.figShareInstitutionString = "plos";
    WombatConfig.doiResolverPrefix = "http://dx.plos.org/";
</script>

<script type="text/javascript">
  var WombatConfig = WombatConfig || {};
  WombatConfig.metrics = WombatConfig.metrics || {};
  WombatConfig.metrics.referenceUrl      = "http://lagotto.io/plos";
  WombatConfig.metrics.googleScholarUrl  = "http://scholar.google.com/scholar";
  WombatConfig.metrics.googleScholarCitationUrl  = WombatConfig.metrics.googleScholarUrl + "?hl=en&lr=&cites=";
  WombatConfig.metrics.crossrefUrl  = "http://www.crossref.org";
</script><script src="//code.jquery.com/jquery-2.1.4.min.js" ></script>
<script>window.jQuery || document.write('<script src="/plosone/resource/js/vendor/jquery-2.1.4.min.js""><\/script>')</script>

          <script type="text/javascript" src="https://widgets.figshare.com/static/figshare.js"></script>










<!--For Google Tag manager to be able to track site information  -->
<script>

  dataLayer = [{
    'mobileSite': 'false',
    'desktopSite': 'true'
  }];

</script>

</head>



<body class="article plosone">


<!-- Google Tag Manager -->
<noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-TP26BH"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
    new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
    j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
    '//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-TP26BH');</script>

<noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-MQQMGF"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
    new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
    j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
    '//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-MQQMGF');</script>
<!-- End Google Tag Manager -->

<header>
  <div id="topslot" class="head-top">

<div class="center">
<div class="title">Advertisement</div>
<!-- DoubleClick Ad Zone -->
  <div class='advertisement' id='div-gpt-ad-1458247671871-0' style='width:728px; height:90px;'>
    <script type='text/javascript'>
      googletag.cmd.push(function() { googletag.display('div-gpt-ad-1458247671871-0'); });
    </script>
  </div>
</div>
  </div>

  <div id="user" class="nav">
    <ul class="nav-user">




      <li ><a href="http://www.plos.org">plos.org</a></li>


        <li ><a href="https://community.plos.org/registration/new">create account</a></li>


          <li class="highlighted"><a href="/plosone/user/secure/login?page=%2Fplosone%2Farticle%3Fid%3D10.1371%2Fjournal.pone.0100206">sign in</a></li>

    </ul>
  </div>
  <div id="pagehdr">

    <nav class="nav-main">




<h1 class="logo">
  <a href="/plosone/.">PLOS ONE</a>
</h1>

<section class="top-bar-section"> 

<ul class="nav-elements">


    <li class="multi-col-parent menu-section-header has-dropdown" id="publish">
    Publish
      <div class="dropdown mega ">
        <ul class="multi-col" id="publish-dropdown-list">

  <li class="menu-section-header " id="submissions">
    <span class="menu-section-header-title">  Submissions </span>

    <ul class="menu-section "
        id="submissions-dropdown-list">
      <li>
    <a href="/plosone/s/getting-started" >Getting Started</a>
  </li>

      <li>
    <a href="/plosone/s/submission-guidelines" >Submission Guidelines</a>
  </li>

      <li>
    <a href="/plosone/s/figures" >Figures</a>
  </li>

      <li>
    <a href="/plosone/s/tables" >Tables</a>
  </li>

      <li>
    <a href="/plosone/s/supporting-information" >Supporting Information</a>
  </li>

      <li>
    <a href="/plosone/s/latex" >LaTeX</a>
  </li>

      <li>
    <a href="/plosone/s/revising-your-manuscript" >Revising Your Manuscript</a>
  </li>

      <li>
    <a href="/plosone/s/submit-now" >Submit Now</a>
  </li>

    </ul>

  </li>


  <li class="menu-section-header " id="policies">
    <span class="menu-section-header-title">  Policies </span>

    <ul class="menu-section "
        id="policies-dropdown-list">
      <li>
    <a href="/plosone/s/best-practices-in-research-reporting" >Best Practices in Research Reporting</a>
  </li>

      <li>
    <a href="/plosone/s/human-subjects-research" >Human Subjects Research</a>
  </li>

      <li>
    <a href="/plosone/s/animal-research" >Animal Research</a>
  </li>

      <li>
    <a href="/plosone/s/competing-interests" >Competing Interests</a>
  </li>

      <li>
    <a href="/plosone/s/disclosure-of-funding-sources" >Disclosure of Funding Sources</a>
  </li>

      <li>
    <a href="/plosone/s/licenses-and-copyright" >Licenses and Copyright</a>
  </li>

      <li>
    <a href="/plosone/s/data-availability" >Data Availability</a>
  </li>

      <li>
    <a href="/plosone/s/materials-and-software-sharing" >Materials and Software Sharing</a>
  </li>

      <li>
    <a href="/plosone/s/ethical-publishing-practice" >Ethical Publishing Practice</a>
  </li>

      <li>
    <a href="/plosone/s/authorship" >Authorship</a>
  </li>

      <li>
    <a href="/plosone/s/downloads-and-translations" >Downloads and Translations</a>
  </li>

    </ul>

  </li>


  <li class="menu-section-header " id="manuscript-review-and-publication">
    <span class="menu-section-header-title">  Manuscript Review and Publication </span>

    <ul class="menu-section "
        id="manuscript-review-and-publication-dropdown-list">
      <li>
    <a href="/plosone/s/criteria-for-publication" >Criteria for Publication</a>
  </li>

      <li>
    <a href="/plosone/s/editorial-and-peer-review-process" >Editorial and Peer Review Process</a>
  </li>

      <li>
    <a href="/plosone/s/reviewer-guidelines" >Reviewer Guidelines</a>
  </li>

      <li>
    <a href="/plosone/s/accepted-manuscripts" >Accepted Manuscripts</a>
  </li>

      <li>
    <a href="/plosone/s/corrections-and-retractions" >Corrections and Retractions</a>
  </li>

      <li>
    <a href="/plosone/s/comments" >Comments</a>
  </li>

      <li>
    <a href="/plosone/s/article-level-metrics" >Article-Level Metrics</a>
  </li>

    </ul>

  </li>
        </ul>
          <div class="calloutcontainer">



  <h3 class="callout-headline">Submit Your Manuscript</h3>

  <div class="action-contain">
  <p class="callout-content">
  Discover a faster, simpler path to publishing in a high-quality journal. <em>PLOS ONE</em> promises fair, rigorous peer review,
  broad scope, and wide readership – a perfect fit for your research every time.
  </p>

  <p class="button-contain special">
    <a class="button button-default" href="/plosone/static/publish">
     Learn More
    </a>
    <a class="button-link" href="http://www.editorialmanager.com/pone/default.asp">
      Submit Now
    </a>
  </p>
  </div>  <!-- opens in siteMenuCalloutDescription -->


          </div>
      </div>
    </li>



  <li class="menu-section-header has-dropdown " id="about">
    <span class="menu-section-header-title">  About </span>

    <ul class="menu-section dropdown "
        id="about-dropdown-list">
      <li>
    <a href="/plosone/static/publish" >Why Publish with PLOS ONE</a>
  </li>

      <li>
    <a href="/plosone/s/journal-information" >Journal Information</a>
  </li>

      <li>
    <a href="/plosone/s/staff-editors" >Staff Editors</a>
  </li>

      <li>
    <a href="/plosone/static/editorial-board" >Editorial Board</a>
  </li>

      <li>
    <a href="/plosone/s/section-editors" >Section Editors</a>
  </li>

      <li>
    <a href="/plosone/s/advisory-groups" >Advisory Groups</a>
  </li>

      <li>
    <a href="/plosone/s/publishing-information" >Publishing Information</a>
  </li>

      <li>
    <a href="/plosone/s/publication-fees" >Publication Fees</a>
  </li>

      <li>
    <a href="/plosone/s/press-and-media" >Press and Media</a>
  </li>

      <li>
    <a href="/plosone/s/contact" >Contact</a>
  </li>

    </ul>

  </li>

  <li data-js-tooltip-hover="trigger" class="subject-area menu-section-header">
  Browse
  </li>




  <li id="navsearch" class="head-search">
    <form name="searchForm" action="/plosone/search" method="get">
      <fieldset>
        <legend>Search</legend>
        <label for="search">Search</label>
        <input id="search" type="text" name="q" placeholder="Search" required/>
        <button id="headerSearchButton" type="submit"><span class="search-icon"></span></button>

      </fieldset>
      <input type="hidden" name="filterJournals" value="PLoSONE"/>
    </form>

    <a id="advSearch"
       href="/plosone/search">
      advanced search
    </a>

  </li>





      </ul>     
      </section>  
    </nav>
  </div>

</header><section id="taxonomyContainer">

<div id="taxonomy-browser" class="areas" data-search-url="/plosone/browse">
  <div class="wrapper">
    <div class="taxonomy-header">
      Browse Subject Areas
      <div id="subjInfo">?</div>
      <div id="subjInfoText">
        <p>Click through the PLOS taxonomy to find articles in your field.</p>
        <p>For more information about PLOS Subject Areas, click
          <a href="/plosone/s/help-using-this-site#loc-subject-areas">here</a>.
        </p>
      </div>
    </div>
    <div class="levels">
      <div class="levels-container cf">
        <div class="levels-position"></div>
      </div>
      <a href="#" class="prev"></a>
      <a href="#" class="next active"></a>
    </div>
  </div>
  <div class="taxonomy-browser-border-bottom"></div>
</div></section>
<main> <div class="set-grid">

<header class="title-block">




<ul id="almSignposts" class="signposts">
  <li id="loadingMetrics">
    <p>Loading metrics</p>
  </li>
</ul>

<script type="text/template" id="signpostsGeneralErrorTemplate">
  <li id="metricsError">Article metrics are unavailable at this time. Please try again later.</li>
</script>

<script type="text/template" id="signpostsNewArticleErrorTemplate">
  <li></li><li></li><li id="tooSoon">Article metrics are unavailable for recently published articles.</li>
</script>

<script type="text/template" id="signpostsTemplate">
    <li id="almSaves">
      <%= s.numberFormat(saveCount, 0) %>
      <div class="tools" data-js-tooltip-hover="trigger">
        <a class="metric-term" href="/plosone/article/metrics?id=10.1371/journal.pone.0100206#savedHeader">Save</a>
        <p class="saves-tip" data-js-tooltip-hover="target"><a href="/plosone/article/metrics?id=10.1371/journal.pone.0100206#savedHeader">Total Mendeley and CiteULike bookmarks.</a></p>
      </div>
    </li>

    <li id="almCitations">
      <%= s.numberFormat(citationCount, 0) %>
      <div class="tools" data-js-tooltip-hover="trigger">
        <a class="metric-term" href="/plosone/article/metrics?id=10.1371/journal.pone.0100206#citedHeader">Citation</a>
        <p class="citations-tip" data-js-tooltip-hover="target"><a href="/plosone/article/metrics?id=10.1371/journal.pone.0100206#citedHeader">Paper's citation count computed by Scopus.</a></p>
      </div>
    </li>

    <li id="almViews">
      <%= s.numberFormat(viewCount, 0) %>
      <div class="tools" data-js-tooltip-hover="trigger">
        <a class="metric-term" href="/plosone/article/metrics?id=10.1371/journal.pone.0100206#viewedHeader">View</a>
        <p class="views-tip" data-js-tooltip-hover="target"><a href="/plosone/article/metrics?id=10.1371/journal.pone.0100206#viewedHeader">Sum of PLOS and PubMed Central page views and downloads.</a></p>
      </div>
    </li>

    <li id="almShares">
      <%= s.numberFormat(shareCount, 0) %>
      <div class="tools" data-js-tooltip-hover="trigger">
        <a class="metric-term" href="/plosone/article/metrics?id=10.1371/journal.pone.0100206#discussedHeader">Share</a>
        <p class="shares-tip" data-js-tooltip-hover="target"><a href="/plosone/article/metrics?id=10.1371/journal.pone.0100206#discussedHeader">Sum of Facebook and Twitter activity.</a></p>
      </div>
    </li>
</script>

    <div class="article-meta">

<div class="classifications">
  <p class="license-short" id="licenseShort">Open Access</p>
  <p class="peer-reviewed" id="peerReviewed">Peer-reviewed</p>

<div class="article-type" >
  <p class="type-article" id="artType">Research Article</p>
</div>


</div>


    </div>
    <div class="article-title-etc">



<div class="title-authors">
  <h1 id="artTitle"><?xml version="1.0" encoding="UTF-8"?>Prognostic Value of <i>Isocitrate Dehydrogenase</i> Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis</h1>

<ul class="author-list clearfix"  data-js-tooltip="tooltip_container" id="author-list">



<li
  data-js-tooltip="tooltip_trigger"
  
>
   <a  data-author-id="0" class="author-name" >
Jie Jin,</a>    <div id="author-meta-0" class="author-info" data-js-tooltip="tooltip_target">

  
  
  <p id="authAffiliations-0"><span class="type">Affiliations</span>
    Department of Hematology, the First Affiliated Hospital of Zhejiang University, Hangzhou, People’s Republic of China, 
    Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
  </p>

      <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose0"> &#x02A2F; </a>
    </div>
</li>

<li
  data-js-tooltip="tooltip_trigger"
  
>
   <a  data-author-id="1" class="author-name" >
Chao Hu,</a>    <div id="author-meta-1" class="author-info" data-js-tooltip="tooltip_target">

  
  
  <p id="authAffiliations-1"><span class="type">Affiliations</span>
    Department of Hematology, the First Affiliated Hospital of Zhejiang University, Hangzhou, People’s Republic of China, 
    Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
  </p>

      <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose1"> &#x02A2F; </a>
    </div>
</li>

<li
  data-js-tooltip="tooltip_trigger"
  
>
   <a  data-author-id="2" class="author-name" >
Mengxia Yu,</a>    <div id="author-meta-2" class="author-info" data-js-tooltip="tooltip_target">

  
  
  <p id="authAffiliations-2"><span class="type">Affiliations</span>
    Department of Hematology, the First Affiliated Hospital of Zhejiang University, Hangzhou, People’s Republic of China, 
    Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
  </p>

      <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose2"> &#x02A2F; </a>
    </div>
</li>

<li
  data-js-tooltip="tooltip_trigger"
  
>
   <a  data-author-id="3" class="author-name" >
Feifei Chen,</a>    <div id="author-meta-3" class="author-info" data-js-tooltip="tooltip_target">

  
  
  <p id="authAffiliations-3"><span class="type">Affiliations</span>
    Department of Hematology, the First Affiliated Hospital of Zhejiang University, Hangzhou, People’s Republic of China, 
    Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
  </p>

      <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose3"> &#x02A2F; </a>
    </div>
</li>

<li
  data-js-tooltip="tooltip_trigger"
  
>
   <a  data-author-id="4" class="author-name" >
Li Ye,</a>    <div id="author-meta-4" class="author-info" data-js-tooltip="tooltip_target">

  
  
  <p id="authAffiliations-4"><span class="type">Affiliations</span>
    Department of Hematology, the First Affiliated Hospital of Zhejiang University, Hangzhou, People’s Republic of China, 
    Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
  </p>

      <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose4"> &#x02A2F; </a>
    </div>
</li>

<li
  data-js-tooltip="tooltip_trigger"
  
>
   <a  data-author-id="5" class="author-name" >
Xiufeng Yin,</a>    <div id="author-meta-5" class="author-info" data-js-tooltip="tooltip_target">

  
  
  <p id="authAffiliations-5"><span class="type">Affiliations</span>
    Department of Hematology, the First Affiliated Hospital of Zhejiang University, Hangzhou, People’s Republic of China, 
    Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
  </p>

      <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose5"> &#x02A2F; </a>
    </div>
</li>

<li
  data-js-tooltip="tooltip_trigger"
  
>
   <a  data-author-id="6" class="author-name" >
Zhengping Zhuang,</a>    <div id="author-meta-6" class="author-info" data-js-tooltip="tooltip_target">

  
  
  <p id="authAffiliations-6"><span class="type">Affiliation</span>
    Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America
  </p>

      <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose6"> &#x02A2F; </a>
    </div>
</li>

<li
  data-js-tooltip="tooltip_trigger"
  
>
   <a  data-author-id="7" class="author-name" >
Hongyan Tong <span class="email">  </span></a>    <div id="author-meta-7" class="author-info" data-js-tooltip="tooltip_target">

  
  <p id="authCorresponding-7"> <span class="email">* E-mail:</span> <a href="mailto:zjuhongyantong@163.com">zjuhongyantong@163.com</a></p>
  <p id="authAffiliations-7"><span class="type">Affiliations</span>
    Department of Hematology, the First Affiliated Hospital of Zhejiang University, Hangzhou, People’s Republic of China, 
    Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
  </p>

      <a data-js-tooltip="tooltip_close" class="close" id="tooltipClose7"> &#x02A2F; </a>
    </div>
</li>

</ul>

</div>


<div id="floatTitleTop" data-js-floater="title_author" class="float-title">
  <div class="set-grid">
    <div class="float-title-inner">
      <h1><?xml version="1.0" encoding="UTF-8"?>Prognostic Value of <i>Isocitrate Dehydrogenase</i> Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis</h1>

<ul id="floatAuthorList" data-js-floater="floated_authors">

  <li data-float-index="1">Jie Jin,&nbsp;

  </li>
  <li data-float-index="2">Chao Hu,&nbsp;

  </li>
  <li data-float-index="3">Mengxia Yu,&nbsp;

  </li>
  <li data-float-index="4">Feifei Chen,&nbsp;

  </li>
  <li data-float-index="5">Li Ye,&nbsp;

  </li>
  <li data-float-index="6">Xiufeng Yin,&nbsp;

  </li>
  <li data-float-index="7">Zhengping Zhuang,&nbsp;

  </li>
  <li data-float-index="8">Hongyan Tong

  </li>

</ul>



    </div>
    <div class="logo-close" id="titleTopCloser">
      <img src="/plosone/resource/img/logo.plos.95.png" alt="PLOS" />
      <div class="close-floater" title="close">x</div>
    </div>
  </div>
</div>

      <ul class="date-doi">
        <li id="artPubDate">Published: June 17, 2014</li>
        <li id="artDoi">
<a   href="https://doi.org/10.1371/journal.pone.0100206">https://doi.org/10.1371/journal.pone.0100206</a>
            </li>
      </ul>

    </div>
  <div>

  </div>
</header>

  <section class="article-body">



<ul class="article-tabs">

        <li class="tab-title active" id="tabArticle">
          <a href="/plosone/article?id=10.1371/journal.pone.0100206" class="article-tab-1">Article</a>
      </li>


            <li class="tab-title " id="tabAuthors">
          <a href="/plosone/article/authors?id=10.1371/journal.pone.0100206" class="article-tab-2">Authors</a>
      </li>


        <li class="tab-title " id="tabMetrics">
          <a href="/plosone/article/metrics?id=10.1371/journal.pone.0100206" class="article-tab-3">Metrics</a>
      </li>

        <li class="tab-title " id="tabComments">
          <a href="/plosone/article/comments?id=10.1371/journal.pone.0100206" class="article-tab-4">Comments</a>
      </li>

        <li class="tab-title " id="tabRelated">
          <a href="/plosone/article/related?id=10.1371/journal.pone.0100206" class="article-tab-5">Related Content</a>
      </li>

</ul>

    <div class="article-container">


<div id="nav-article">
  <ul class="nav-secondary">

    <li class="nav-comments" id="nav-comments">
      <a href="article/comments?id=10.1371/journal.pone.0100206">Reader Comments (0)</a>
    </li>

    <li class="nav-media" id="nav-media" data-doi="10.1371/journal.pone.0100206">
      <a href="/plosone/article/related?id=10.1371/journal.pone.0100206">
        Media Coverage <span id="media-coverage-count"></span>
      </a>
    </li>

    <li id="nav-figures"><a href="#" data-doi="10.1371/journal.pone.0100206">Figures</a></li>
  </ul>
</div>

<div id="figure-lightbox-container"></div>

<script id="figure-lightbox-template" type="text/template">
  <div id="figure-lightbox" class="reveal-modal full" data-reveal aria-hidden="true"
       role="dialog">
    <div class="lb-header">
      <h1 id="lb-title"><%= articleTitle %></h1>

      <div id="lb-authors">
        <% authorList.split(',').forEach(function (author) { %>
        <span><%= author.trim() %></span>
        <% }) %>
      </div>

      <div class="lb-close" title="close">&nbsp;</div>
    </div>
    <div class="img-container">
      <div class="loader"> <i class="fa-spinner"></i> </div>
      <img class="main-lightbox-image" src=""/>
      <aside id="figures-list">
        <% figureList.each(function (ix, figure) { %>
        <div class="change-img" data-doi="<%= figure.getAttribute('data-doi') %>">
          <img class="aside-figure" src="/plosone/article/figure/image?size=inline&id=<%= figure.getAttribute('data-doi') %>" />
        </div>
        <% }) %>
        <div class="dummy-figure">
        </div>
      </aside>
    </div>
    <div id="lightbox-footer">

      <div id="btns-container" class="lightbox-row <% if(figureList.length <= 1) { print('one-figure-only') } %>">
        <div class="fig-btns-container reset-zoom-wrapper left">
          <span class="fig-btn reset-zoom-btn">Reset zoom</span>
        </div>
        <div class="zoom-slider-container">
          <div class="range-slider-container">
            <span id="lb-zoom-min"></span>
            <div class="range-slider round" data-slider data-options="start: 20; end: 200; initial: 20;">
              <span class="range-slider-handle" role="slider" tabindex="0"></span>
              <span class="range-slider-active-segment"></span>
              <input type="hidden">
            </div>
            <span id="lb-zoom-max"></span>
          </div>
        </div>
        <% if(figureList.length > 1) { %>
        <div class="fig-btns-container">
          <span class="fig-btn all-fig-btn"><i class="icon icon-all"></i> All Figures</span>
          <span class="fig-btn next-fig-btn"><i class="icon icon-next"></i> Next</span>
          <span class="fig-btn prev-fig-btn"><i class="icon icon-prev"></i> Previous</span>
        </div>
        <% } %>
      </div>
      <div id="image-context">
      </div>
    </div>
  </div>
</script>

<script id="image-context-template" type="text/template">
  <div class="footer-text">
    <div id="figure-description-wrapper">
      <div id="view-more-wrapper" style="<% descriptionExpanded? print('display:none;') : '' %>">
        <span id="figure-title"><%= title %></span>
        <p id="figure-description">
          <%= description %>&nbsp;&nbsp;
        </p>
        <span id="view-more">show more<i class="icon-arrow-right"></i></span>

      </div>
      <div id="view-less-wrapper" style="<% descriptionExpanded? print('display:inline-block;') : '' %>" >
        <span id="figure-title"><%= title %></span>
        <p id="full-figure-description">
          <%= description %>&nbsp;&nbsp;
          <span id="view-less">show less<i class="icon-arrow-left"></i></span>
        </p>
      </div>
    </div>
  </div>
  <div id="show-context-container">
    <a class="btn show-context" href="<%= showInContext(strippedDoi) %>">Show in Context</a>
  </div>
  <div id="download-buttons">
    <h3>Download:</h3>
    <div class="item">
      <a href="/plosone/article/figure/image?size=original&download=&id=<%= doi %>" title="original image">
        <span class="download-btn">TIFF</span>
      </a>
      <span class="file-size"><%= fileSizes.original %></span>
    </div>
    <div class="item">
      <a href="/plosone/article/figure/image?size=large&download=&id=<%= doi %>" title="large image">
        <span class="download-btn">PNG</span>
      </a>
      <span class="file-size"><%= fileSizes.large %></span>
    </div>
    <div class="item">
      <a href="/plosone/article/figure/powerpoint?id=<%= doi %>" title="PowerPoint slide">
        <span class="download-btn">PPT</span>
      </a>
    </div>

  </div>
</script>
      <div class="article-content">








<div id="figure-carousel-section">
  <h2>Figures</h2>

  <div id="figure-carousel">

    <div class="carousel-wrapper">
      <div class="slider">

          <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pone.0100206.g001">

                <img src="/plosone/article/figure/image?size=inline&amp;id=10.1371/journal.pone.0100206.g001"
                     alt="Figure 1"
                />

            </div>

          <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pone.0100206.t001">

                <img src="/plosone/article/figure/image?size=inline&amp;id=10.1371/journal.pone.0100206.t001"
                     alt="Table 1"
                />

            </div>

          <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pone.0100206.g002">

                <img src="/plosone/article/figure/image?size=inline&amp;id=10.1371/journal.pone.0100206.g002"
                     alt="Figure 2"
                />

            </div>

          <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pone.0100206.g003">

                <img src="/plosone/article/figure/image?size=inline&amp;id=10.1371/journal.pone.0100206.g003"
                     alt="Figure 3"
                />

            </div>

          <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pone.0100206.t002">

                <img src="/plosone/article/figure/image?size=inline&amp;id=10.1371/journal.pone.0100206.t002"
                     alt="Table 2"
                />

            </div>

          <div class="carousel-item lightbox-figure" data-doi="10.1371/journal.pone.0100206.g004">

                <img src="/plosone/article/figure/image?size=inline&amp;id=10.1371/journal.pone.0100206.g004"
                     alt="Figure 4"
                />

            </div>
      </div>
    </div>

    <div class="carousel-control">
      <span class="button previous"></span>
      <span class="button next"></span>
    </div>
    <div class="carousel-page-buttons">

    </div>
  </div>
</div>


        <div class="article-text" id="artText">
        



<div class="abstract toc-section"><a id="abstract0" name="abstract0" data-toc="abstract0" class="link-target" title="Abstract"></a><h2>Abstract</h2>
<div id="section1" class="section toc-section"><a id="" name="" class="link-target" title="Background"></a>
<h3>Background</h3>
<a id="article1.front1.article-meta1.abstract1.sec1.p1" name="article1.front1.article-meta1.abstract1.sec1.p1" class="link-target"></a><p>Recent genomic sequencing efforts have identified a number of recurrent mutations in myelodysplastic syndromes (MDS) that may contribute to disease progression and overall survival, including mutations in <em>isocitrate dehydrogenases 1</em> and <em>2</em> (<em>IDH1</em> and <em>IDH2</em>).</p>
</div>

<div id="section2" class="section toc-section"><a id="" name="" class="link-target" title="Methods"></a>
<h3>Methods</h3>
<a id="article1.front1.article-meta1.abstract1.sec2.p1" name="article1.front1.article-meta1.abstract1.sec2.p1" class="link-target"></a><p>Pretreatment bone marrow (BM) samples were acquired from mononuclear cells in 146 adult patients with de novo MDS from January 2006 to June 2013. Polymerase chain reaction (PCR) and direct sequencing were performed on exon 4 of <em>IDH1/2</em> genes and mutation status was correlated with overall survival (OS) and leukemia-free survival (LFS). We then performed a meta-analysis combining previously published and current studies to explore the effect of <em>IDH</em> mutations on OS and LFS in MDS.</p>
</div>

<div id="section3" class="section toc-section"><a id="" name="" class="link-target" title="Results"></a>
<h3>Results</h3>
<a id="article1.front1.article-meta1.abstract1.sec3.p1" name="article1.front1.article-meta1.abstract1.sec3.p1" class="link-target"></a><p>In our study, somatic mutations of either <em>IDH</em> gene were discovered in 11 MDS patients (7.53%) and were significantly correlated with poorer OS (<em>P</em> = 0.007). <em>IDH</em> mutations were specifically associated with a poorer OS in the intermediate-1 risk group by the International Prognostic Scoring System (IPSS) (<em>P</em> = 0.039). In addition, we discovered decitabine achieved a better therapeutic effect compared to other treatments in <em>IDH</em> mutation-positive patients (<em>P</em> = 0.023). We identified six previous studies of <em>IDH</em> mutations in MDS. A meta-analysis of these studies included 111 MDS patients <em>IDH</em> mutations and 1671 MDS patients with wild-type <em>IDH1/2</em>. The hazard ratios (HRs) of OS and LFS for patients with <em>IDH</em> mutations were 1.62 (95% CI, 1.27–2.09) and 2.21 (95% CI, 1.48–3.30), respectively.</p>
</div>

<div id="section4" class="section toc-section"><a id="" name="" class="link-target" title="Conclusion"></a>
<h3>Conclusion</h3>
<a id="article1.front1.article-meta1.abstract1.sec4.p1" name="article1.front1.article-meta1.abstract1.sec4.p1" class="link-target"></a><p>The results from our study and the meta-analysis provide firm evidence that <em>IDH</em> mutations are significantly associated with poorer clinical outcomes in MDS. Identification of <em>IDH</em> mutations may be pivotal for better risk stratification in MDS patients and improving IPSS score. Additionally, hypomethylating agents may be an effective treatment option for MDS patients with <em>IDH</em> mutations.</p>
</div>
</div>


<div class="articleinfo"><p><strong>Citation: </strong>Jin J, Hu C, Yu M, Chen F, Ye L, Yin X, et al.  (2014) Prognostic Value of <em>Isocitrate Dehydrogenase</em> Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis. PLoS ONE 9(6):
        e100206.
        https://doi.org/10.1371/journal.pone.0100206</p><p><strong>Editor: </strong>Zhuang Zuo, UT MD Anderson Cancer Center, United States of America</p><p><strong>Received: </strong>January 19, 2014; <strong>Accepted: </strong>May 21, 2014; <strong>Published: </strong> June 17, 2014</p><p><strong>Copyright: </strong> © 2014 Jin et al. This is an open-access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p><p><strong>Funding: </strong>This study was supported by grants from Zhejiang Province Fund for Distinguished Young Scholars (LR12H08001), the Foundation of Key Innovation Team of Zhejiang Province (2011R50015), National Public Health Grand Research Foundation (201202017), major program of Science Technology Department of Zhejiang Province fund (2013c03043-2) and the National Natural Science Foundation of China (No.30870914, No.81270582). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p><p><strong>Competing interests: </strong> The authors have declared that no competing interests exist.</p></div>





<div id="section1" class="section toc-section"><a id="s1" name="s1" data-toc="s1" class="link-target" title="Introduction"></a><h2>Introduction</h2><a id="article1.body1.sec1.p1" name="article1.body1.sec1.p1" class="link-target"></a><p>Myelodysplastic syndromes (MDS) comprise a heterogeneous group of hematological disorders defined by blood cytopenias due to ineffective hematopoiesis and an increased risk of developing acute myeloid leukemia (AML) <a href="#pone.0100206-Corey1" class="ref-tip">[1]</a>, <a href="#pone.0100206-Nimer1" class="ref-tip">[2]</a>. Despite recent advances in therapeutic methods, treatments for MDS are currently tailored to individual patient needs, making the precise forecast of the prognosis an important component of treating patients <a href="#pone.0100206-Bejar1" class="ref-tip">[3]</a>. Current prognostic scoring systems for patients with MDS are mainly based on karyotypic abnormalities and certain clinical features that are used to stratify risk. Although existing systems such as the IPSS <a href="#pone.0100206-Greenberg1" class="ref-tip">[4]</a>, Revised-IPSS <a href="#pone.0100206-Greenberg2" class="ref-tip">[5]</a> and WHO-classification-based Prognostic Scoring System (WPSS) <a href="#pone.0100206-Malcovati1" class="ref-tip">[6]</a> help to estimate patient outcomes and guide treatment decisions, there remains significant variability in prognosis. Hence, novel molecular markers may offer more precise cancer phenotypes and more accurate estimation of prognosis for MDS patients.</p>
<a id="article1.body1.sec1.p2" name="article1.body1.sec1.p2" class="link-target"></a><p>Until now, the pathogenesis of MDS has not been clearly identified, but it is generally acknowledged that genetic mutations and dysfunction of gene contribute to the development and progression of this preleukemic disease <a href="#pone.0100206-Bejar2" class="ref-tip">[7]</a>, <a href="#pone.0100206-Shih1" class="ref-tip">[8]</a>. Genetic mutations are not currently used in estimating prognosis in MDS but are likely key determinants of overall survival and clinical phenotypes <a href="#pone.0100206-GarciaManero1" class="ref-tip">[9]</a>. Therefore, contributing gene mutations may supplement current prognostic systems to improve the prediction of prognosis for MDS patients.</p>
<a id="article1.body1.sec1.p3" name="article1.body1.sec1.p3" class="link-target"></a><p>IDH 1/2 are key metabolic enzymes that convert isocitrate to α-ketoglutarate (α-KG or 2-oxoglutarate, 2-OG), which is an essential cofactor for α-KG dependent dioxygenases <a href="#pone.0100206-Reitman1" class="ref-tip">[10]</a>, <a href="#pone.0100206-Chung1" class="ref-tip">[11]</a>. These enzymes are associated with diverse cellular processes such as adapting to histone deacetylation, hypoxia, and DNA demethylation <a href="#pone.0100206-Kaelin1" class="ref-tip">[12]</a>. Therefore, <em>IDH</em> mutations may be causally linked to the clinical impacts of patients with MDS. We identified 146 patients with primary MDS and analysed <em>IDH</em> mutation status with OS and LFS. We then performed a meta-analysis combining our data with those of the published literature to furnish a more accurate estimation of the relationship between <em>IDH</em> mutations and MDS.</p>
</div>

<div id="section2" class="section toc-section"><a id="s2" name="s2" data-toc="s2" class="link-target" title="Methods"></a><h2>Methods</h2>
<div id="section1" class="section toc-section"><a id="s2a" name="s2a" class="link-target" title="Patients"></a>
<h3>Patients</h3>
<a id="article1.body1.sec2.sec1.p1" name="article1.body1.sec2.sec1.p1" class="link-target"></a><p>One hundred and forty-six adult patients with de novo MDS diagnosed according to World Health Organization (WHO) 2001 criteria <a href="#pone.0100206-Vardiman1" class="ref-tip">[13]</a> were recruited at the department of hematology, the First Affiliated Hospital of Zhejiang University. MDS patients were stratified by cytogenetic risk according to IPSS protocols <a href="#pone.0100206-Greenberg1" class="ref-tip">[4]</a>. All of the subjects were well-informed about the study and provided written informed consent to participate this study. This study was approved by the Institutional Review boards of the First Affiliated Hospital of Zhejiang University. Follow-up data were obtained by telephoning and reviewing patients’ medical records. 7 of 146 patients (4.79%) were lost to follow-up. Treatments were performed for patients including chemotherapy regimens (the GAA regimen (granulocyte-colony stimulating factor (G-CSF) 200 µg/m<sup>2</sup> per day on days 1–14, aclacinomycin 10 mg per day on days 1–14; cytarabine 10 mg/m<sup>2</sup>, days 1–14; n = 2); the GHA regimen (G-CSF 200 µg/m<sup>2</sup> per day on days 1–14, homoharringtonine 1 mg/m<sup>2</sup> per day on days 1–14, cytarabine 10 mg/m<sup>2</sup> per day on days 1–14; n = 6); the DA or IA regimen (daunorubicin 40–45 mg/m<sup>2</sup> per day on days 1–3 or idarubicin 8–12 mg/m<sup>2</sup> per day on days 1–3, cytarabine 100 mg/m<sup>2</sup> per day on days 1–7; n = 8); decitabine (20 mg/m<sup>2</sup>/day, days 1–5 or 15 mg/m<sup>2</sup>, q8 h, days 1–3; n = 44)) and supportive care (antibiotics, androgen, all-<em>trans</em> retinoic acid, blood product transfusion and iron chelation therapy; n = 86).</p>
</div>

<div id="section2" class="section toc-section"><a id="s2b" name="s2b" class="link-target" title="Mutational Analyses for the IDH1 and IDH2 Genes"></a>
<h3>Mutational Analyses for the IDH1 and IDH2 Genes</h3>
<a id="article1.body1.sec2.sec2.p1" name="article1.body1.sec2.sec2.p1" class="link-target"></a><p>Pretreatment BM specimens were enriched for mononuclear cells using Ficoll density gradient centrifugation. Genomic DNA was extracted from cryopreserved mononuclear cells using the DNA Kit (Sangon, Shanghai, China) according to the manufacturer’s instructions. Approximately 100 ng of DNA was used for each PCR reaction. The primer pairs were the same as those designed by Patnaik et al <a href="#pone.0100206-Patnaik1" class="ref-tip">[14]</a>. The PCR amplification conditions were as follows: 95°C for 5 minutes; followed by 40 cycles of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 seconds; and finally, 72°C for 5 minutes. PCR products were directly sequenced on both strands using an ABI 3730 automatic sequencer by Sangon.</p>
</div>

<div id="section3" class="section toc-section"><a id="s2c" name="s2c" class="link-target" title="Statistical Analysis"></a>
<h3>Statistical Analysis</h3>
<a id="article1.body1.sec2.sec3.p1" name="article1.body1.sec2.sec3.p1" class="link-target"></a><p>OS end-points were defined as the time from diagnosis of MDS to death due to any cause or to the time of last follow-up. LFS end-points were defined as the time from MDS diagnosis to either AML progression or death or failure or alive without disease progression at the date of most recent follow-up. Length of survival comparisons were analyzed using the Kaplan-Meier method. For categorical parameters, overall group differences were compared with the χ<sup>2</sup> or Fisher exact test. For continuous variables, overall group differences were evaluated with the Mann-Whitney <em>U</em> test. A Cox proportional hazards model was performed to evaluate the effect of endpoint on OS and LFS for multivariate analysis. Statistical analysis was performed with SPSS 16.0 software package (SPSS, Chicago, USA). All tests were 2-tailed, and a <em>P</em>-value of less than 0.05 was considered statistically significant.</p>
</div>

<div id="section4" class="section toc-section"><a id="s2d" name="s2d" class="link-target" title="Meta-analysis of IDH1/2 Mutations in MDS"></a>
<h3>Meta-analysis of <em>IDH1/2</em> Mutations in MDS</h3>
<a id="article1.body1.sec2.sec4.p1" name="article1.body1.sec2.sec4.p1" class="link-target"></a><p>To further assess the relationship between <em>IDH1/2</em> mutations and MDS risk, we conducted a meta-analysis combining our study data with published studies on <em>IDH</em> mutations in MDS <a href="#pone.0100206-Bejar1" class="ref-tip">[3]</a>, <a href="#pone.0100206-Patnaik1" class="ref-tip">[14]</a>, <a href="#pone.0100206-Thol1" class="ref-tip">[15]</a>, <a href="#pone.0100206-Lin1" class="ref-tip">[16]</a>, <a href="#pone.0100206-Lin2" class="ref-tip">[17]</a>, <a href="#pone.0100206-Lin3" class="ref-tip">[18]</a>. Two independent reviewers (CH and MXY) performed a systematic literature search using ISI Web of Science, PubMed and the Cochrane Library for relevant papers published before December 2013 by the search term “(MDS OR myelodysplastic syndrome OR preleukemia OR myelodysplasia) AND (<em>IDH1</em> OR <em>IDH2</em>).” Reviews and references of related articles were checked for missing information. Eligible papers met all the following criteria: (1) assessed the association between <em>IDH1/2</em> mutations and outcomes in MDS; (2) detailed survival information of patients with <em>IDH1</em> or <em>IDH2</em> mutations; (3) reported the study in English. Animal studies, letters to the editor without original data, reviews and case reports were excluded. In the event of multiple publications from overlapping study populations or the same study, only the one with the largest sample size was selected (<a href="#pone-0100206-g001">Figure 1</a>).</p>
<a class="link-target" id="pone-0100206-g001" name="pone-0100206-g001"></a><div class="figure" data-doi="10.1371/journal.pone.0100206.g001"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&amp;id=info:doi/10.1371/journal.pone.0100206.g001" data-doi="info:doi/10.1371/journal.pone.0100206" data-uri="info:doi/10.1371/journal.pone.0100206.g001"><img src="article/figure/image?size=inline&amp;id=info:doi/10.1371/journal.pone.0100206.g001" alt="thumbnail" class="thumbnail"></a><div class="expand"></div></div><div class="figure-inline-download">
          Download:
          <ul><li><div class="definition-label"><a href="article/figure/powerpoint?id=info:doi/10.1371/journal.pone.0100206.g001">
                  PPT
                </a></div><a href="article/figure/powerpoint?id=info:doi/10.1371/journal.pone.0100206.g001">
                PowerPoint slide
              </a></li><li><div class="definition-label"><a href="article/figure/image?download&amp;size=large&amp;id=info:doi/10.1371/journal.pone.0100206.g001">
                  PNG
                </a></div><a href="article/figure/image?download&amp;size=large&amp;id=info:doi/10.1371/journal.pone.0100206.g001">
                larger image
              </a></li><li><div class="definition-label"><a href="article/figure/image?download&amp;size=original&amp;id=info:doi/10.1371/journal.pone.0100206.g001">
                  TIFF
                </a></div><a href="article/figure/image?download&amp;size=original&amp;id=info:doi/10.1371/journal.pone.0100206.g001">
                original image
              </a></li></ul></div><div class="figcaption"><span>Figure 1. </span> Flow diagram of study selection.</div><p class="caption_target"></p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pone.0100206.g001">
              https://doi.org/10.1371/journal.pone.0100206.g001</a></p></div><a id="article1.body1.sec2.sec4.p2" name="article1.body1.sec2.sec4.p2" class="link-target"></a><p>The following data were extracted from each article: first author’s name, year of publication, country of origin, participant gender, participant age, sample size, MDS subtype, criteria for classification of MDS, karyotypes and IPSS classification. If the required data for the meta-analysis were not available in the published study, we contacted the corresponding authors for missing data.</p>
<a id="article1.body1.sec2.sec4.p3" name="article1.body1.sec2.sec4.p3" class="link-target"></a><p>A general variance-based method and a mathematical HR approximation method <a href="#pone.0100206-Tierney1" class="ref-tip">[19]</a> in this meta-analysis were simultaneously used to estimate the summary HRs and their 95% CIs for the combined large sample set. Assessing heterogeneity and choosing fixed-effect or random-effect were performed as described previously <a href="#pone.0100206-Tong1" class="ref-tip">[20]</a>. Sensitivity analysis was conducted by sequential omission of individual studies and evaluated influence of each study on the stability of the results. Cumulative analysis was performed by assortment of publication time. Publication bias was assessed by funnel plot and Egger’s test <a href="#pone.0100206-Begg1" class="ref-tip">[21]</a>, <a href="#pone.0100206-Egger1" class="ref-tip">[22]</a>. All statistical analyses were carried out in STATA 11.0 statistical software (Stata Corporation, College Station, Texas), and a <em>P</em>-value less than 0.05 was considered significant.</p>
</div>
</div>

<div id="section3" class="section toc-section"><a id="s3" name="s3" data-toc="s3" class="link-target" title="Results"></a><h2>Results</h2>
<div id="section1" class="section toc-section"><a id="s3a" name="s3a" class="link-target" title="Patient Characteristics"></a>
<h3>Patient Characteristics</h3>
<a id="article1.body1.sec3.sec1.p1" name="article1.body1.sec3.sec1.p1" class="link-target"></a><p>The current study included 146 patients (85 men and 61 women). The median age was 55 years (range 18–85). According to the WHO criteria, 7 (4.79%) patients were classified as refractory anemia (RA), 3 (2.05%) as RA with ringed sideroblasts (RARS), 50 (34.25%) as refractory cytopenia with multilineage dysplasia (RCMD), 44 (30.14%) as RA with excess blasts type 1 (RAEB1) and 42 (28.77%) as RAEB2 <a href="#pone.0100206-Bennett1" class="ref-tip">[23]</a>. Cytogenetic results were available for 141 patients. The data demonstrated a low risk in 99 patients, an intermediate risk in 26 patients and a high risk in 16 patients. IPSS risk distributions were: low risk in 7 patients (4.97%), intermediate-1 risk in 76 patients (53.90%), intermediate-2 risk in 46 patients (32.62%) and high risk in 12 patients (8.51%).</p>
</div>

<div id="section2" class="section toc-section"><a id="s3b" name="s3b" class="link-target" title="IDH1/2 Mutations in MDS and Association with Clinical Outcomes"></a>
<h3><em>IDH1/2</em> Mutations in MDS and Association with Clinical Outcomes</h3>
<a id="article1.body1.sec3.sec2.p1" name="article1.body1.sec3.sec2.p1" class="link-target"></a><p><em>IDH1/2</em> mutations were identified in eleven (7.53%) MDS patients, six (4.11%) had mutations in <em>IDH1</em> and five (3.42%) had mutations in <em>IDH2</em> (<a href="#pone-0100206-t001">Table 1</a>). Among MDS patients with <em>IDH1/2</em> mutations, two (18.18%) were classified as RAEB1, seven (63.64%) as RAEB2 and two (18.18%) as RCMD. Seven MDS patients (64.64%) with <em>IDH</em> mutations had a normal karyotype. Of the four patients with <em>IDH1/2</em> mutations and abnormal karyotypes, three (75%) carried a −7/7q-. All MDS patients with <em>IDH1</em> mutations carried an <em>IDH1</em> R132C mutation, whereas all patients with <em>IDH2</em> mutations carried an <em>IDH2</em> R140Q mutation. <em>IDH1/2</em> mutants carried significantly more bone marrow (BM) blasts than MDS patients with wild-type <em>IDH1/2</em> (<em>P</em> = 0.022); no significant differences were observed in age, sex, white blood cell (WBC) count, hemoglobin, platelet count, WHO subtype, cytogenetics or IPSS.</p>
<a class="link-target" id="pone-0100206-t001" name="pone-0100206-t001"></a><div class="figure" data-doi="10.1371/journal.pone.0100206.t001"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&amp;id=info:doi/10.1371/journal.pone.0100206.t001" data-doi="info:doi/10.1371/journal.pone.0100206" data-uri="info:doi/10.1371/journal.pone.0100206.t001"><img src="article/figure/image?size=inline&amp;id=info:doi/10.1371/journal.pone.0100206.t001" alt="thumbnail" class="thumbnail"></a><div class="expand"></div></div><div class="figure-inline-download">
          Download:
          <ul><li><div class="definition-label"><a href="article/figure/powerpoint?id=info:doi/10.1371/journal.pone.0100206.t001">
                  PPT
                </a></div><a href="article/figure/powerpoint?id=info:doi/10.1371/journal.pone.0100206.t001">
                PowerPoint slide
              </a></li><li><div class="definition-label"><a href="article/figure/image?download&amp;size=large&amp;id=info:doi/10.1371/journal.pone.0100206.t001">
                  PNG
                </a></div><a href="article/figure/image?download&amp;size=large&amp;id=info:doi/10.1371/journal.pone.0100206.t001">
                larger image
              </a></li><li><div class="definition-label"><a href="article/figure/image?download&amp;size=original&amp;id=info:doi/10.1371/journal.pone.0100206.t001">
                  TIFF
                </a></div><a href="article/figure/image?download&amp;size=original&amp;id=info:doi/10.1371/journal.pone.0100206.t001">
                original image
              </a></li></ul></div><div class="figcaption"><span>Table 1. </span> Characteristics of patients with MDS.</div><p class="caption_target"></p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pone.0100206.t001">
              https://doi.org/10.1371/journal.pone.0100206.t001</a></p></div><a id="article1.body1.sec3.sec2.p2" name="article1.body1.sec3.sec2.p2" class="link-target"></a><p>The median survival time was 512 days (range 100–924 days) in the <em>IDH1/2</em> mutant group and 956 days (range, 632–1280 days) in the wild-type <em>IDH1/2</em> group. Survival analysis demonstrated MDS patients harboring <em>IDH1/2</em> mutations had significantly shorter OS compared to patients with wild-type <em>IDH1/2</em> (<em>P</em> = 0.007) (<a href="#pone-0100206-g002">Figure 2A</a>). Further, we found <em>IDH1</em> mutations negatively affected OS in MDS (<em>P</em> = 0.030) rather than <em>IDH2</em> mutations (<em>P</em> = 0.067) (<a href="#pone-0100206-g002">Figure 2C, E</a>). The presence of <em>IDH1/2</em> mutations did not influence the LFS (<em>P</em> = 0.078, 0.195 and 0.201, respectively) (<a href="#pone-0100206-g002">Figure 2B, D, F</a>). Interestingly, our data showed the presence of <em>IDH1/2</em> mutations was an adverse predictor of OS in the intermediate-1 risk group of IPSS (<em>P</em> = 0.039) (<a href="#pone-0100206-g003">Figure 3A</a>), but not in the intermediate-2 risk (<em>P</em> = 0.410) (<a href="#pone-0100206-g003">Figure 3B</a>) or high risk (<em>P</em> = 0.685) (<a href="#pone-0100206-g003">Figure 3C</a>) group. Our results also indicated that decitabine achieved a better therapeutic effect in <em>IDH1/2</em> mutation-positive patients compared to other treatments (including: GHA regimen, n = 3; GAA regimen, n = 2; supportive care, n = 2) (<em>P</em> = 0.023) (<a href="#pone-0100206-g003">Figure 3D</a>).</p>
<a class="link-target" id="pone-0100206-g002" name="pone-0100206-g002"></a><div class="figure" data-doi="10.1371/journal.pone.0100206.g002"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&amp;id=info:doi/10.1371/journal.pone.0100206.g002" data-doi="info:doi/10.1371/journal.pone.0100206" data-uri="info:doi/10.1371/journal.pone.0100206.g002"><img src="article/figure/image?size=inline&amp;id=info:doi/10.1371/journal.pone.0100206.g002" alt="thumbnail" class="thumbnail"></a><div class="expand"></div></div><div class="figure-inline-download">
          Download:
          <ul><li><div class="definition-label"><a href="article/figure/powerpoint?id=info:doi/10.1371/journal.pone.0100206.g002">
                  PPT
                </a></div><a href="article/figure/powerpoint?id=info:doi/10.1371/journal.pone.0100206.g002">
                PowerPoint slide
              </a></li><li><div class="definition-label"><a href="article/figure/image?download&amp;size=large&amp;id=info:doi/10.1371/journal.pone.0100206.g002">
                  PNG
                </a></div><a href="article/figure/image?download&amp;size=large&amp;id=info:doi/10.1371/journal.pone.0100206.g002">
                larger image
              </a></li><li><div class="definition-label"><a href="article/figure/image?download&amp;size=original&amp;id=info:doi/10.1371/journal.pone.0100206.g002">
                  TIFF
                </a></div><a href="article/figure/image?download&amp;size=original&amp;id=info:doi/10.1371/journal.pone.0100206.g002">
                original image
              </a></li></ul></div><div class="figcaption"><span>Figure 2. </span> Kaplan–Meier survival curves for survival of MDS patients.</div><p class="caption_target"><a id="article1.body1.sec3.sec2.fig1.caption1.p1" name="article1.body1.sec3.sec2.fig1.caption1.p1" class="link-target"></a><p>(A) Overall survival data for MDS patients stratified by <em>IDH1/2</em> mutational status. (B) Leukemia-free survival data for MDS patients stratified by <em>IDH1/2</em> mutational status. (C) Overall survival data for MDS patients stratified by <em>IDH1</em> mutational status. (D) Leukemia-free survival data for MDS patients stratified by <em>IDH1</em> mutational status. (E) Overall survival data for MDS patients stratified by <em>IDH2</em> mutational status. (F) Leukemia-free survival data for MDS patients stratified by <em>IDH2</em> mutational status.</p>
</p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pone.0100206.g002">
              https://doi.org/10.1371/journal.pone.0100206.g002</a></p></div><a class="link-target" id="pone-0100206-g003" name="pone-0100206-g003"></a><div class="figure" data-doi="10.1371/journal.pone.0100206.g003"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&amp;id=info:doi/10.1371/journal.pone.0100206.g003" data-doi="info:doi/10.1371/journal.pone.0100206" data-uri="info:doi/10.1371/journal.pone.0100206.g003"><img src="article/figure/image?size=inline&amp;id=info:doi/10.1371/journal.pone.0100206.g003" alt="thumbnail" class="thumbnail"></a><div class="expand"></div></div><div class="figure-inline-download">
          Download:
          <ul><li><div class="definition-label"><a href="article/figure/powerpoint?id=info:doi/10.1371/journal.pone.0100206.g003">
                  PPT
                </a></div><a href="article/figure/powerpoint?id=info:doi/10.1371/journal.pone.0100206.g003">
                PowerPoint slide
              </a></li><li><div class="definition-label"><a href="article/figure/image?download&amp;size=large&amp;id=info:doi/10.1371/journal.pone.0100206.g003">
                  PNG
                </a></div><a href="article/figure/image?download&amp;size=large&amp;id=info:doi/10.1371/journal.pone.0100206.g003">
                larger image
              </a></li><li><div class="definition-label"><a href="article/figure/image?download&amp;size=original&amp;id=info:doi/10.1371/journal.pone.0100206.g003">
                  TIFF
                </a></div><a href="article/figure/image?download&amp;size=original&amp;id=info:doi/10.1371/journal.pone.0100206.g003">
                original image
              </a></li></ul></div><div class="figcaption"><span>Figure 3. </span> Kaplan–Meier survival curves for overall survival of MDS patients.</div><p class="caption_target"><a id="article1.body1.sec3.sec2.fig2.caption1.p1" name="article1.body1.sec3.sec2.fig2.caption1.p1" class="link-target"></a><p>(A) Overall survival of MDS patients in the intermediate-1 risk group of IPSS. (B) Overall survival of MDS patients in the intermediate-2 risk group of IPSS. (C) Overall survival of MDS patients in the high risk group of IPSS. (D) Kaplan–Meier survival of <em>IDH</em> mutant patients with decitabine chemotherapy compared with other treatments.</p>
</p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pone.0100206.g003">
              https://doi.org/10.1371/journal.pone.0100206.g003</a></p></div><a id="article1.body1.sec3.sec2.p3" name="article1.body1.sec3.sec2.p3" class="link-target"></a><p>Multivariable analysis including <em>IDH</em> mutations, age, WBC count, hemoglobin, platelet count, BM blast count, cytogenetic changes and IPSS class showed HRs of <em>IDH1/2</em> mutations for OS and LFS were 1.83 (95%CI 0.86–3.92) (<em>P</em> = 0.118) and 1.18 (95%CI 0.56–2.50) (<em>P</em> = 0.662), respectively. In addition, HRs of mutant <em>IDH1</em> for OS and LFS were 1.62 (95%CI 0.55–4.81) (<em>P</em> = 0.383) and 1.07 (95%CI 0.37–3.09) (<em>P</em> = 0.903), and HRs of mutant <em>IDH2</em> for OS and LFS were 1.93 (95%CI 0.70–5.35) (<em>P</em> = 0.206) and 1.23 (95%CI 0.44–3.40) (<em>P</em> = 0.692), respectively.</p>
</div>

<div id="section3" class="section toc-section"><a id="s3c" name="s3c" class="link-target" title="Meta-analysis Results"></a>
<h3>Meta-analysis Results</h3>
<a id="article1.body1.sec3.sec3.p1" name="article1.body1.sec3.sec3.p1" class="link-target"></a><p>As shown in <a href="#pone-0100206-g001">Figure 1</a>, six studies and our data covering a total of 1782 subjects (111 with <em>IDH1/2</em> mutations, 1671 with wild-type <em>IDH</em>) were included in the meta-analysis. Two of them were from United States <a href="#pone.0100206-Bejar1" class="ref-tip">[3]</a>, <a href="#pone.0100206-Patnaik1" class="ref-tip">[14]</a>, one from Germany <a href="#pone.0100206-Thol1" class="ref-tip">[15]</a> and three from Asia <a href="#pone.0100206-Lin1" class="ref-tip">[16]</a>, <a href="#pone.0100206-Lin2" class="ref-tip">[17]</a>, <a href="#pone.0100206-Lin3" class="ref-tip">[18]</a> (<a href="#pone-0100206-t002">Table 2</a>). Two of these studies found a correlation between <em>IDH1/2</em> mutations and adverse prognosis in MDS <a href="#pone.0100206-Patnaik1" class="ref-tip">[14]</a>, <a href="#pone.0100206-Thol1" class="ref-tip">[15]</a>. For all studies in this meta-analysis, MDS were diagnosed by the WHO <a href="#pone.0100206-Vardiman1" class="ref-tip">[13]</a> or FAB (French-American-British) criteria <a href="#pone.0100206-Bennett2" class="ref-tip">[24]</a>.</p>
<a class="link-target" id="pone-0100206-t002" name="pone-0100206-t002"></a><div class="figure" data-doi="10.1371/journal.pone.0100206.t002"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&amp;id=info:doi/10.1371/journal.pone.0100206.t002" data-doi="info:doi/10.1371/journal.pone.0100206" data-uri="info:doi/10.1371/journal.pone.0100206.t002"><img src="article/figure/image?size=inline&amp;id=info:doi/10.1371/journal.pone.0100206.t002" alt="thumbnail" class="thumbnail"></a><div class="expand"></div></div><div class="figure-inline-download">
          Download:
          <ul><li><div class="definition-label"><a href="article/figure/powerpoint?id=info:doi/10.1371/journal.pone.0100206.t002">
                  PPT
                </a></div><a href="article/figure/powerpoint?id=info:doi/10.1371/journal.pone.0100206.t002">
                PowerPoint slide
              </a></li><li><div class="definition-label"><a href="article/figure/image?download&amp;size=large&amp;id=info:doi/10.1371/journal.pone.0100206.t002">
                  PNG
                </a></div><a href="article/figure/image?download&amp;size=large&amp;id=info:doi/10.1371/journal.pone.0100206.t002">
                larger image
              </a></li><li><div class="definition-label"><a href="article/figure/image?download&amp;size=original&amp;id=info:doi/10.1371/journal.pone.0100206.t002">
                  TIFF
                </a></div><a href="article/figure/image?download&amp;size=original&amp;id=info:doi/10.1371/journal.pone.0100206.t002">
                original image
              </a></li></ul></div><div class="figcaption"><span>Table 2. </span> Main characteristics of studies involving in the meta-analysis.</div><p class="caption_target"></p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pone.0100206.t002">
              https://doi.org/10.1371/journal.pone.0100206.t002</a></p></div><a id="article1.body1.sec3.sec3.p2" name="article1.body1.sec3.sec3.p2" class="link-target"></a><p>The summary HRs for OS were 1.62 (95% CI, 1.27–2.09) for <em>IDH1/2</em> mutations (<a href="#pone-0100206-g004">Figure 4A</a>), and 2.21 (95% CI, 1.45–3.38) for <em>IDH1</em> mutations (<a href="#pone-0100206-g004">Figure 4C</a>), indicating that the presence of <em>IDH1</em> mutations was a negative prognostic factor for OS, whereas a marginal association was discovered for <em>IDH2</em> mutations 1.38 (95% CI, 0.95–2.02) (<a href="#pone-0100206-g004">Figure 4E</a>). <a href="#pone-0100206-g004">Figure 4B and 4D</a> showed the results of meta analysis for LFS, the summary HRs of LFS were 2.21 (95% CI, 1.48–3.30) for <em>IDH1/2</em> mutations and 2.65 (95% CI, 1.53–4.59) for <em>IDH1</em> mutations. There was moderate heterogeneity among studies (<em>I<sup>2</sup></em>&lt;75%), but no publication bias was found. Since significant heterogeneity across studies was detected, we executed sensitivity analyses and the results demonstrated the robust stability of the current results.</p>
<a class="link-target" id="pone-0100206-g004" name="pone-0100206-g004"></a><div class="figure" data-doi="10.1371/journal.pone.0100206.g004"><div class="img-box"><a title="Click for larger image" href="article/figure/image?size=medium&amp;id=info:doi/10.1371/journal.pone.0100206.g004" data-doi="info:doi/10.1371/journal.pone.0100206" data-uri="info:doi/10.1371/journal.pone.0100206.g004"><img src="article/figure/image?size=inline&amp;id=info:doi/10.1371/journal.pone.0100206.g004" alt="thumbnail" class="thumbnail"></a><div class="expand"></div></div><div class="figure-inline-download">
          Download:
          <ul><li><div class="definition-label"><a href="article/figure/powerpoint?id=info:doi/10.1371/journal.pone.0100206.g004">
                  PPT
                </a></div><a href="article/figure/powerpoint?id=info:doi/10.1371/journal.pone.0100206.g004">
                PowerPoint slide
              </a></li><li><div class="definition-label"><a href="article/figure/image?download&amp;size=large&amp;id=info:doi/10.1371/journal.pone.0100206.g004">
                  PNG
                </a></div><a href="article/figure/image?download&amp;size=large&amp;id=info:doi/10.1371/journal.pone.0100206.g004">
                larger image
              </a></li><li><div class="definition-label"><a href="article/figure/image?download&amp;size=original&amp;id=info:doi/10.1371/journal.pone.0100206.g004">
                  TIFF
                </a></div><a href="article/figure/image?download&amp;size=original&amp;id=info:doi/10.1371/journal.pone.0100206.g004">
                original image
              </a></li></ul></div><div class="figcaption"><span>Figure 4. </span> Forest plots describing the association between <em>IDH</em> mutations and MDS.</div><p class="caption_target"><a id="article1.body1.sec3.sec3.fig1.caption1.p1" name="article1.body1.sec3.sec3.fig1.caption1.p1" class="link-target"></a><p>(A) Forest plots of HR and 95% CI for <em>IDH1/2</em> mutations in MDS comparing with <em>IDH</em> wild-type by OS endpoints. (B) Forest plots of HR and 95% CI for <em>IDH1/2</em> mutations in MDS comparing with IDH wild-type by LFS endpoints. (C) Forest plots of HR and 95% CI for <em>IDH</em>1 mutations in MDS comparing with <em>IDH</em>1 wild-type by OS endpoints. (D) Forest plots of HR and 95% CI for <em>IDH</em>1 mutations in MDS comparing with <em>IDH</em>1 wild-type by LFS endpoints. (E) Forest plots of HR and 95% CI for <em>IDH</em>2 mutations in MDS comparing with <em>IDH</em>2 wild-type by OS endpoints. (F) Forest plots of cumulative meta-analysis of <em>IDH</em> mutations in association with MDS for OS by published year.</p>
</p><p class="caption_object"><a href="https://doi.org/10.1371/journal.pone.0100206.g004">
              https://doi.org/10.1371/journal.pone.0100206.g004</a></p></div><a id="article1.body1.sec3.sec3.p3" name="article1.body1.sec3.sec3.p3" class="link-target"></a><p>Cumulative analysis of the relationship between <em>IDH</em> mutations and MDS was performed via the assortment of studies by publication time. Inclinations toward significant association were evident over time. Moreover, the 95% CI became increasingly narrow with accumulation of more data, indicating the exactness of estimates was progressively boosted by the addition of more subjects (<a href="#pone-0100206-g004">Figure 4F</a>).</p>
</div>
</div>

<div id="section4" class="section toc-section"><a id="s4" name="s4" data-toc="s4" class="link-target" title="Discussion"></a><h2>Discussion</h2><a id="article1.body1.sec4.p1" name="article1.body1.sec4.p1" class="link-target"></a><p>Due to the heterogeneity that still exists in the current prognostic scoring systems of MDS, the inclusion of novel molecular markers in these systems may enhance prognostic information. Although single gene mutations are not currently included in prognostic scoring systems, they may be vital to clinical phenotypes and overall survival in MDS. Actually, a great number of single gene mutations including <em>EZH2</em>, <em>SF3B1</em>, <em>TET2</em>, <em>ASXL1</em> and <em>TP53</em> have been associated with the development of MDS <a href="#pone.0100206-Tothova1" class="ref-tip">[25]</a>, <a href="#pone.0100206-Muto1" class="ref-tip">[26]</a>. The illumination of new gene mutations may therefore improve the prevention, diagnosis, prognosis and treatment of MDS.</p>
<a id="article1.body1.sec4.p2" name="article1.body1.sec4.p2" class="link-target"></a><p>IDH is a key cytosolic enzyme in the Krebs cycle. It catalyzes the decarboxylation of isocitrate to α-KG, leading to the production of nicotinamide adenine dinucleotide phosphate (NADP) <a href="#pone.0100206-Krell1" class="ref-tip">[27]</a>, <a href="#pone.0100206-Jin1" class="ref-tip">[28]</a>. <em>IDH</em> mutations were first reported in a metastatic colon cancer in 2006 <a href="#pone.0100206-Sjoblom1" class="ref-tip">[29]</a>, and then since 2010 recurring <em>IDH</em> mutations were successively found in MDS (3.42%∼12.27%) <a href="#pone.0100206-Bejar1" class="ref-tip">[3]</a>, <a href="#pone.0100206-Patnaik1" class="ref-tip">[14]</a>, <a href="#pone.0100206-Lin2" class="ref-tip">[17]</a>, <a href="#pone.0100206-Yoshida1" class="ref-tip">[30]</a>, <a href="#pone.0100206-Rocquain1" class="ref-tip">[31]</a>, <a href="#pone.0100206-Kosmider1" class="ref-tip">[32]</a>. <em>IDH</em> mutations impair the normal enzymes’ function, which may be associated with poor prognosis in MDS. However, prior studies have not provided a definitive link between <em>IDH</em> mutations and MDS. Meta-analysis is a useful statistical method for integrating results from independent studies for a specified outcome. Combining the relevant studies increases statistical power and thus makes it possible to detect effects that may be missed by individual studies. Therefore, we summarized here the current data available regarding this potential relationship and revealed several valuable points.</p>
<a id="article1.body1.sec4.p3" name="article1.body1.sec4.p3" class="link-target"></a><p>Firstly we discovered a significant relationship between <em>IDH1/2</em> mutations status and MDS prognosis in the Chinese population, <em>IDH</em> mutations predicted more adverse OS for patients with MDS (<em>P</em> = 0.007). Furthermore, a meta-analysis combining the current and six previously published studies on <em>IDH1/2</em> mutations and MDS indicated <em>IDH1/2</em> mutations negatively affected OS (HR, 1.62; 95% CI, 1.27–2.09) and LFS 2.21 (95% CI, 1.48–3.30). Cumulative analysis further confirmed the significant correlation, demonstrating the effect of the variant became progressively significant with each accumulation of more data over time. In addition, when we conducted subgroup analyses, our data illustrated that <em>IDH1</em> but not <em>IDH2</em> mutations negatively affected OS 2.21 (95% CI, 1.45–3.38) and LFS 2.65 (95% CI, 1.53–4.59) in patients with MDS. Secondly, the presence of <em>IDH1/2</em> mutations might subdivide the intermediate-1 IPSS risk group as this was associated with a shorter OS in this group (<em>P</em> = 0.039). Finally, we found <em>IDH1/2</em> mutation-positive patients with MDS who were treated with decitibine had a significantly longer OS (<em>P</em> = 0.023) suggesting hypomethylating agents might be an effective treatment option for these patients.</p>
<a id="article1.body1.sec4.p4" name="article1.body1.sec4.p4" class="link-target"></a><p>There are several mechanisms by which <em>IDH1/2</em> mutations can worsen the prognosis of patients with MDS. (1) <em>IDH</em> mutations occur at low frequency (3.42%–12.27%) in MDS, but <em>IDH1/2</em> mutations are more frequent in both de novo AML (7.5%–31%) and AML arising from MDS (7.5%) <a href="#pone.0100206-Thol1" class="ref-tip">[15]</a>, <a href="#pone.0100206-Abbas1" class="ref-tip">[33]</a>, <a href="#pone.0100206-Pardanani1" class="ref-tip">[34]</a>, <a href="#pone.0100206-Tefferi1" class="ref-tip">[35]</a>, <a href="#pone.0100206-Chou1" class="ref-tip">[36]</a>, <a href="#pone.0100206-Chou2" class="ref-tip">[37]</a>, indicating a role for <em>IDH</em> mutations in leukemic transformation of MDS. (2) At the cytogenetic level, Caramazza et al. <a href="#pone.0100206-Caramazza1" class="ref-tip">[38]</a> showed a likely association between <em>IDH1/2</em> mutations and trisomy 8 in MDS, and our results demonstrated 75% (3/4) of <em>IDH1/2</em> mutants with abnormal karyotypes carried a −7/7q- karyotype. In MDS, +8 and −7/7q- karyotypes were categorized in the intermediate-risk and high-risk cytogenetic group, respectively, suggesting they were linked to poor outcome in MDS. (3) The mutant IDH proteins displayed a gain of function as they could convert the α-KG that was generated by wild-type IDH proteins into 2-hydroxyglutarate (2-HG). Recent studies <a href="#pone.0100206-Fathi1" class="ref-tip">[39]</a>, <a href="#pone.0100206-Dinardo1" class="ref-tip">[40]</a> reported that 2-HG was closely related to therapeutic response and relapse in AML. Since MDS and AML share many similar characteristics <a href="#pone.0100206-Steensma1" class="ref-tip">[41]</a>, it is possible that 2-HG is an oncogenic factor in MDS. (4) DNA hypermethylation played a vital role in MDS pathogenesis <a href="#pone.0100206-Khan1" class="ref-tip">[42]</a>. Dang et al <a href="#pone.0100206-Dang1" class="ref-tip">[43]</a> reported that mutant IDH1/2 proteins produced 2-HG which competitively inhibited α-KG-dependent enzymes, such as the DNA demethylating protein TET2 (Ten-eleven translocation 2) resulting in DNA hypermethylation. Indeed, Figueroa et al. <a href="#pone.0100206-Figueroa1" class="ref-tip">[44]</a> found that AML patients with <em>IDH1/2</em> mutations shared a similar methylation profile to those with <em>TET2</em> mutations, and both mutations led to a block in myeloid differentiation and leukemogenesis. This might also be a potential reason for affecting outcomes in MDS. (5) Accumulation of 2-HG might lead to DNA damage by generating reactive oxygen species (ROS) <a href="#pone.0100206-Ward1" class="ref-tip">[45]</a> and inhibit EGLN (Egg-laying defective Nine) with subsequent stabilization of hypoxia-inducible factor 1α (HIF-1α) <a href="#pone.0100206-Zhao1" class="ref-tip">[46]</a>. DNA damage and HIF-1α stabilization have been reported to be closely linked to MDS pathogenesis <a href="#pone.0100206-Tong2" class="ref-tip">[47]</a>, <a href="#pone.0100206-Head1" class="ref-tip">[48]</a>. There are thus several mechanisms by which <em>IDH1/2</em> mutations may contribute to MDS pathophysiology but further research is needed to elucidate their exact contributions to the disease.</p>
<a id="article1.body1.sec4.p5" name="article1.body1.sec4.p5" class="link-target"></a><p>While the findings of this study are largely consistent with previous studies on <em>IDH1/2</em> mutations in MDS, several limitations should be addressed. First, analyses were based on observational rather than experimental studies. Cohort studies are prone to several types of bias including selection bias and loss-to-follow-up <a href="#pone.0100206-Grimes1" class="ref-tip">[49]</a>. Second, we did not uncover unpublished studies and chose to collect only published articles in English, which could bring publication bias, despite there being no significant evidence of publication bias observed in Egger’s test. Third, our study did not assess the potential effects of gene-gene interactions known to influence outcome in MDS such as <em>TET2</em> mutation-associated hypermethylation <a href="#pone.0100206-Figueroa1" class="ref-tip">[44]</a>. Similarly, we did not account for other known genetic contributions to leukemic transformation in MDS such as <em>ASXL1</em> loss-of-function <a href="#pone.0100206-AbdelWahab1" class="ref-tip">[50]</a>. This could lead to possible confounding in our study results. However, since <em>IDH1/2</em> mutations and <em>TET2</em> mutations were previously found to be mutually exclusive in patients with AML <a href="#pone.0100206-Figueroa1" class="ref-tip">[44]</a>, it is not likely this particular interaction significantly contributed to our results.</p>
<a id="article1.body1.sec4.p6" name="article1.body1.sec4.p6" class="link-target"></a><p>In conclusion, we screened exon 4 of the <em>IDH1/2</em> gene in a large cohort of Chinese patients with MDS. Consistent with previous observations, we found that <em>IDH</em> mutations were present in some patients with MDS. <em>IDH1</em> mutations rather than <em>IDH2</em> mutations were significantly associated with shorter OS and LFS in patients with MDS. Further studies with larger sample sizes and functional assays of mutant IDH proteins are essential to decipher the role of <em>IDH</em> mutations in the development of MDS. Given that <em>IDH</em> mutations may adversely affect outcome in MDS are relatively easy to assess at diagnosis, examining <em>IDH</em> mutations in MDS may enhance the current prognostic scoring systems and guide patient-specific treatment in MDS. Finally, the identification of <em>IDH</em> mutations in the development and progression of MDS offers the promise of ameliorating the disease using targeted therapeutics against this biochemical pathway.</p>
</div>

<div id="section5" class="section toc-section"><a id="s5" name="s5" data-toc="s5" class="link-target" title="Supporting Information"></a><h2>Supporting Information</h2><div class="figshare_widget" doi="10.1371/journal.pone.0100206"></div><div class="supplementary-material"><a name="pone.0100206.s001" id="pone.0100206.s001" class="link-target"></a><h3 class="siTitle title-small"><a href="article/file?type=supplementary&amp;id=info:doi/10.1371/journal.pone.0100206.s001">Checklist S1. </a></h3><a id="article1.body1.sec5.supplementary-material1.caption1.p1" name="article1.body1.sec5.supplementary-material1.caption1.p1" class="link-target"></a><p class="preSiDOI">PRISMA checklist.</p>
<p class="siDoi"><a href="https://doi.org/10.1371/journal.pone.0100206.s001">https://doi.org/10.1371/journal.pone.0100206.s001</a></p><a id="article1.body1.sec5.supplementary-material1.caption1.p2" name="article1.body1.sec5.supplementary-material1.caption1.p2" class="link-target"></a><p class="postSiDOI">(DOC)</p>
</div></div>





<div class="section toc-section"><a id="ack" name="ack" data-toc="ack" title="Acknowledgments" class="link-target"></a><h2>Acknowledgments</h2>
<a id="article1.back1.ack1.p1" name="article1.back1.ack1.p1" class="link-target"></a><p>We sincerely thank the sample donors and clinical investigators who participated in this study. We sincerely thank Swallows Cody from NIH for the job in polishing our paper. We are deeply indebted to Pro. Bejar R and Pro. Ebert BL from Harvard Medical School and Brigham and Women’s Hospital for supplying us original data.</p>
</div><div class="contributions toc-section"><a id="authcontrib" name="authcontrib" data-toc="authcontrib" title="Author Contributions"></a><h2>Author Contributions</h2><p>Conceived and designed the experiments: JJ HT ZZ. Performed the experiments: CH MY LY. Analyzed the data: CH FC XY. Contributed reagents/materials/analysis tools: CH. Wrote the paper: CH HT.</p></div><div class="toc-section"><a id="references" name="references" class="link-target" data-toc="references" title="References"></a><h2>References</h2><ol class="references"><li id="ref1"><span class="order">1.
            </span><a name="pone.0100206-Corey1" id="pone.0100206-Corey1" class="link-target"></a>Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, et al. (2007) Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 7: 118–129. <ul class="reflinks"><li><a href="#" data-author="Corey" data-cit="CoreySJ%2C%20MindenMD%2C%20BarberDL%2C%20KantarjianH%2C%20WangJC%2C%20et%20al.%20%282007%29%20Myelodysplastic%20syndromes%3A%20the%20complexity%20of%20stem-cell%20diseases.%20Nat%20Rev%20Cancer%207%3A%20118%E2%80%93129." data-title="Myelodysplastic%20syndromes%3A%20the%20complexity%20of%20stem-cell%20diseases" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Corey%5Bauthor%5D+AND+Myelodysplastic+syndromes%3A+the+complexity+of+stem-cell+diseases" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Myelodysplastic+syndromes%3A+the+complexity+of+stem-cell+diseases&amp;author=Corey&amp;publication_year=2007" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref2"><span class="order">2.
            </span><a name="pone.0100206-Nimer1" id="pone.0100206-Nimer1" class="link-target"></a>Nimer SD (2008) Myelodysplastic syndromes. Blood 111: 4841–4851. <ul class="reflinks"><li><a href="#" data-author="Nimer" data-cit="NimerSD%20%282008%29%20Myelodysplastic%20syndromes.%20Blood%20111%3A%204841%E2%80%934851." data-title="Myelodysplastic%20syndromes" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Nimer%5Bauthor%5D+AND+Myelodysplastic+syndromes" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Myelodysplastic+syndromes&amp;author=Nimer&amp;publication_year=2008" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref3"><span class="order">3.
            </span><a name="pone.0100206-Bejar1" id="pone.0100206-Bejar1" class="link-target"></a>Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, et al. (2011) Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364: 2496–2506. <ul class="reflinks"><li><a href="#" data-author="Bejar" data-cit="BejarR%2C%20StevensonK%2C%20Abdel-WahabO%2C%20GaliliN%2C%20NilssonB%2C%20et%20al.%20%282011%29%20Clinical%20effect%20of%20point%20mutations%20in%20myelodysplastic%20syndromes.%20N%20Engl%20J%20Med%20364%3A%202496%E2%80%932506." data-title="Clinical%20effect%20of%20point%20mutations%20in%20myelodysplastic%20syndromes" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Bejar%5Bauthor%5D+AND+Clinical+effect+of+point+mutations+in+myelodysplastic+syndromes" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Clinical+effect+of+point+mutations+in+myelodysplastic+syndromes&amp;author=Bejar&amp;publication_year=2011" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref4"><span class="order">4.
            </span><a name="pone.0100206-Greenberg1" id="pone.0100206-Greenberg1" class="link-target"></a>Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, et al. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079–2088. <ul class="reflinks"><li><a href="#" data-author="Greenberg" data-cit="GreenbergP%2C%20CoxC%2C%20LeBeauMM%2C%20FenauxP%2C%20MorelP%2C%20et%20al.%20%281997%29%20International%20scoring%20system%20for%20evaluating%20prognosis%20in%20myelodysplastic%20syndromes.%20Blood%2089%3A%202079%E2%80%932088." data-title="International%20scoring%20system%20for%20evaluating%20prognosis%20in%20myelodysplastic%20syndromes" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Greenberg%5Bauthor%5D+AND+International+scoring+system+for+evaluating+prognosis+in+myelodysplastic+syndromes" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=International+scoring+system+for+evaluating+prognosis+in+myelodysplastic+syndromes&amp;author=Greenberg&amp;publication_year=1997" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref5"><span class="order">5.
            </span><a name="pone.0100206-Greenberg2" id="pone.0100206-Greenberg2" class="link-target"></a>Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, et al. (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120: 2454–2465. <ul class="reflinks"><li><a href="#" data-author="Greenberg" data-cit="GreenbergPL%2C%20TuechlerH%2C%20SchanzJ%2C%20SanzG%2C%20Garcia-ManeroG%2C%20et%20al.%20%282012%29%20Revised%20international%20prognostic%20scoring%20system%20for%20myelodysplastic%20syndromes.%20Blood%20120%3A%202454%E2%80%932465." data-title="Revised%20international%20prognostic%20scoring%20system%20for%20myelodysplastic%20syndromes" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Greenberg%5Bauthor%5D+AND+Revised+international+prognostic+scoring+system+for+myelodysplastic+syndromes" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Revised+international+prognostic+scoring+system+for+myelodysplastic+syndromes&amp;author=Greenberg&amp;publication_year=2012" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref6"><span class="order">6.
            </span><a name="pone.0100206-Malcovati1" id="pone.0100206-Malcovati1" class="link-target"></a>Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, et al. (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25: 3503–3510. <ul class="reflinks"><li><a href="#" data-author="Malcovati" data-cit="MalcovatiL%2C%20GermingU%2C%20KuendgenA%2C%20Della%20PortaMG%2C%20PascuttoC%2C%20et%20al.%20%282007%29%20Time-dependent%20prognostic%20scoring%20system%20for%20predicting%20survival%20and%20leukemic%20evolution%20in%20myelodysplastic%20syndromes.%20J%20Clin%20Oncol%2025%3A%203503%E2%80%933510." data-title="Time-dependent%20prognostic%20scoring%20system%20for%20predicting%20survival%20and%20leukemic%20evolution%20in%20myelodysplastic%20syndromes" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Malcovati%5Bauthor%5D+AND+Time-dependent+prognostic+scoring+system+for+predicting+survival+and+leukemic+evolution+in+myelodysplastic+syndromes" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Time-dependent+prognostic+scoring+system+for+predicting+survival+and+leukemic+evolution+in+myelodysplastic+syndromes&amp;author=Malcovati&amp;publication_year=2007" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref7"><span class="order">7.
            </span><a name="pone.0100206-Bejar2" id="pone.0100206-Bejar2" class="link-target"></a>Bejar R, Levine R, Ebert BL (2011) Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 29: 504–515. <ul class="reflinks"><li><a href="#" data-author="Bejar" data-cit="BejarR%2C%20LevineR%2C%20EbertBL%20%282011%29%20Unraveling%20the%20molecular%20pathophysiology%20of%20myelodysplastic%20syndromes.%20J%20Clin%20Oncol%2029%3A%20504%E2%80%93515." data-title="Unraveling%20the%20molecular%20pathophysiology%20of%20myelodysplastic%20syndromes" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Bejar%5Bauthor%5D+AND+Unraveling+the+molecular+pathophysiology+of+myelodysplastic+syndromes" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Unraveling+the+molecular+pathophysiology+of+myelodysplastic+syndromes&amp;author=Bejar&amp;publication_year=2011" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref8"><span class="order">8.
            </span><a name="pone.0100206-Shih1" id="pone.0100206-Shih1" class="link-target"></a>Shih AH, Levine RL (2011) Molecular biology of myelodysplastic syndromes. Semin Oncol 38: 613–620. <ul class="reflinks"><li><a href="#" data-author="Shih" data-cit="ShihAH%2C%20LevineRL%20%282011%29%20Molecular%20biology%20of%20myelodysplastic%20syndromes.%20Semin%20Oncol%2038%3A%20613%E2%80%93620." data-title="Molecular%20biology%20of%20myelodysplastic%20syndromes" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Shih%5Bauthor%5D+AND+Molecular+biology+of+myelodysplastic+syndromes" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Molecular+biology+of+myelodysplastic+syndromes&amp;author=Shih&amp;publication_year=2011" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref9"><span class="order">9.
            </span><a name="pone.0100206-GarciaManero1" id="pone.0100206-GarciaManero1" class="link-target"></a>Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, et al. (2008) A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22: 538–543. <ul class="reflinks"><li><a href="#" data-author="Garcia-Manero" data-cit="Garcia-ManeroG%2C%20ShanJ%2C%20FaderlS%2C%20CortesJ%2C%20RavandiF%2C%20et%20al.%20%282008%29%20A%20prognostic%20score%20for%20patients%20with%20lower%20risk%20myelodysplastic%20syndrome.%20Leukemia%2022%3A%20538%E2%80%93543." data-title="A%20prognostic%20score%20for%20patients%20with%20lower%20risk%20myelodysplastic%20syndrome" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Garcia-Manero%5Bauthor%5D+AND+A+prognostic+score+for+patients+with+lower+risk+myelodysplastic+syndrome" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=A+prognostic+score+for+patients+with+lower+risk+myelodysplastic+syndrome&amp;author=Garcia-Manero&amp;publication_year=2008" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref10"><span class="order">10.
            </span><a name="pone.0100206-Reitman1" id="pone.0100206-Reitman1" class="link-target"></a>Reitman ZJ, Yan H (2010) Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 102: 932–941. <ul class="reflinks"><li><a href="#" data-author="Reitman" data-cit="ReitmanZJ%2C%20YanH%20%282010%29%20Isocitrate%20dehydrogenase%201%20and%202%20mutations%20in%20cancer%3A%20alterations%20at%20a%20crossroads%20of%20cellular%20metabolism.%20J%20Natl%20Cancer%20Inst%20102%3A%20932%E2%80%93941." data-title="Isocitrate%20dehydrogenase%201%20and%202%20mutations%20in%20cancer%3A%20alterations%20at%20a%20crossroads%20of%20cellular%20metabolism" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Reitman%5Bauthor%5D+AND+Isocitrate+dehydrogenase+1+and+2+mutations+in+cancer%3A+alterations+at+a+crossroads+of+cellular+metabolism" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Isocitrate+dehydrogenase+1+and+2+mutations+in+cancer%3A+alterations+at+a+crossroads+of+cellular+metabolism&amp;author=Reitman&amp;publication_year=2010" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref11"><span class="order">11.
            </span><a name="pone.0100206-Chung1" id="pone.0100206-Chung1" class="link-target"></a>Chung YR, Schatoff E, Abdel-Wahab O (2012) Epigenetic alterations in hematopoietic malignancies. Int J Hematol 96: 413–427. <ul class="reflinks"><li><a href="#" data-author="Chung" data-cit="ChungYR%2C%20SchatoffE%2C%20Abdel-WahabO%20%282012%29%20Epigenetic%20alterations%20in%20hematopoietic%20malignancies.%20Int%20J%20Hematol%2096%3A%20413%E2%80%93427." data-title="Epigenetic%20alterations%20in%20hematopoietic%20malignancies" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Chung%5Bauthor%5D+AND+Epigenetic+alterations+in+hematopoietic+malignancies" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Epigenetic+alterations+in+hematopoietic+malignancies&amp;author=Chung&amp;publication_year=2012" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref12"><span class="order">12.
            </span><a name="pone.0100206-Kaelin1" id="pone.0100206-Kaelin1" class="link-target"></a>Kaelin WG Jr (2011) Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb Symp Quant Biol 76: 335–345. <ul class="reflinks"><li><a href="#" data-author="Kaelin" data-cit="KaelinWGJr%20%282011%29%20Cancer%20and%20altered%20metabolism%3A%20potential%20importance%20of%20hypoxia-inducible%20factor%20and%202-oxoglutarate-dependent%20dioxygenases.%20Cold%20Spring%20Harb%20Symp%20Quant%20Biol%2076%3A%20335%E2%80%93345." data-title="Cancer%20and%20altered%20metabolism%3A%20potential%20importance%20of%20hypoxia-inducible%20factor%20and%202-oxoglutarate-dependent%20dioxygenases" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Kaelin%5Bauthor%5D+AND+Cancer+and+altered+metabolism%3A+potential+importance+of+hypoxia-inducible+factor+and+2-oxoglutarate-dependent+dioxygenases" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Cancer+and+altered+metabolism%3A+potential+importance+of+hypoxia-inducible+factor+and+2-oxoglutarate-dependent+dioxygenases&amp;author=Kaelin&amp;publication_year=2011" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref13"><span class="order">13.
            </span><a name="pone.0100206-Vardiman1" id="pone.0100206-Vardiman1" class="link-target"></a>Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100: 2292–2302. <ul class="reflinks"><li><a href="#" data-author="Vardiman" data-cit="VardimanJW%2C%20HarrisNL%2C%20BrunningRD%20%282002%29%20The%20World%20Health%20Organization%20%28WHO%29%20classification%20of%20the%20myeloid%20neoplasms.%20Blood%20100%3A%202292%E2%80%932302." data-title="The%20World%20Health%20Organization%20%28WHO%29%20classification%20of%20the%20myeloid%20neoplasms" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Vardiman%5Bauthor%5D+AND+The+World+Health+Organization+%28WHO%29+classification+of+the+myeloid+neoplasms" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=The+World+Health+Organization+%28WHO%29+classification+of+the+myeloid+neoplasms&amp;author=Vardiman&amp;publication_year=2002" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref14"><span class="order">14.
            </span><a name="pone.0100206-Patnaik1" id="pone.0100206-Patnaik1" class="link-target"></a>Patnaik MM, Hanson CA, Hodnefield JM, Lasho TL, Finke CM, et al. (2012) Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia 26: 101–105. <ul class="reflinks"><li><a href="#" data-author="Patnaik" data-cit="PatnaikMM%2C%20HansonCA%2C%20HodnefieldJM%2C%20LashoTL%2C%20FinkeCM%2C%20et%20al.%20%282012%29%20Differential%20prognostic%20effect%20of%20IDH1%20versus%20IDH2%20mutations%20in%20myelodysplastic%20syndromes%3A%20a%20Mayo%20Clinic%20study%20of%20277%20patients.%20Leukemia%2026%3A%20101%E2%80%93105." data-title="Differential%20prognostic%20effect%20of%20IDH1%20versus%20IDH2%20mutations%20in%20myelodysplastic%20syndromes%3A%20a%20Mayo%20Clinic%20study%20of%20277%20patients" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Patnaik%5Bauthor%5D+AND+Differential+prognostic+effect+of+IDH1+versus+IDH2+mutations+in+myelodysplastic+syndromes%3A+a+Mayo+Clinic+study+of+277+patients" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Differential+prognostic+effect+of+IDH1+versus+IDH2+mutations+in+myelodysplastic+syndromes%3A+a+Mayo+Clinic+study+of+277+patients&amp;author=Patnaik&amp;publication_year=2012" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref15"><span class="order">15.
            </span><a name="pone.0100206-Thol1" id="pone.0100206-Thol1" class="link-target"></a>Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, et al. (2010) IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 95: 1668–1674. <ul class="reflinks"><li><a href="#" data-author="Thol" data-cit="TholF%2C%20WeissingerEM%2C%20KrauterJ%2C%20WagnerK%2C%20DammF%2C%20et%20al.%20%282010%29%20IDH1%20mutations%20in%20patients%20with%20myelodysplastic%20syndromes%20are%20associated%20with%20an%20unfavorable%20prognosis.%20Haematologica%2095%3A%201668%E2%80%931674." data-title="IDH1%20mutations%20in%20patients%20with%20myelodysplastic%20syndromes%20are%20associated%20with%20an%20unfavorable%20prognosis" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Thol%5Bauthor%5D+AND+IDH1+mutations+in+patients+with+myelodysplastic+syndromes+are+associated+with+an+unfavorable+prognosis" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=IDH1+mutations+in+patients+with+myelodysplastic+syndromes+are+associated+with+an+unfavorable+prognosis&amp;author=Thol&amp;publication_year=2010" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref16"><span class="order">16.
            </span><a name="pone.0100206-Lin1" id="pone.0100206-Lin1" class="link-target"></a>Lin J, Yao DM, Qian J, Chen Q, Qian W, et al. (2012) IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol 91: 519–525. <ul class="reflinks"><li><a href="#" data-author="Lin" data-cit="LinJ%2C%20YaoDM%2C%20QianJ%2C%20ChenQ%2C%20QianW%2C%20et%20al.%20%282012%29%20IDH1%20and%20IDH2%20mutation%20analysis%20in%20Chinese%20patients%20with%20acute%20myeloid%20leukemia%20and%20myelodysplastic%20syndrome.%20Ann%20Hematol%2091%3A%20519%E2%80%93525." data-title="IDH1%20and%20IDH2%20mutation%20analysis%20in%20Chinese%20patients%20with%20acute%20myeloid%20leukemia%20and%20myelodysplastic%20syndrome" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Lin%5Bauthor%5D+AND+IDH1+and+IDH2+mutation+analysis+in+Chinese+patients+with+acute+myeloid+leukemia+and+myelodysplastic+syndrome" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=IDH1+and+IDH2+mutation+analysis+in+Chinese+patients+with+acute+myeloid+leukemia+and+myelodysplastic+syndrome&amp;author=Lin&amp;publication_year=2012" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref17"><span class="order">17.
            </span><a name="pone.0100206-Lin2" id="pone.0100206-Lin2" class="link-target"></a>Lin TL, Nagata Y, Kao HW, Sanada M, Okuno Y, et al. (2013) Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations. Haematologica. <ul class="reflinks"><li><a href="#" data-author="Lin" data-cit="LinTL%2C%20NagataY%2C%20KaoHW%2C%20SanadaM%2C%20OkunoY%2C%20et%20al.%20%282013%29%20Clonal%20leukemic%20evolution%20in%20myelodysplastic%20syndromes%20with%20TET2%20and%20IDH1%2F2%20mutations.%20Haematologica." data-title="Clonal%20leukemic%20evolution%20in%20myelodysplastic%20syndromes%20with%20TET2%20and%20IDH1%2F2%20mutations" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Lin%5Bauthor%5D+AND+Clonal+leukemic+evolution+in+myelodysplastic+syndromes+with+TET2+and+IDH1%2F2+mutations" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Clonal+leukemic+evolution+in+myelodysplastic+syndromes+with+TET2+and+IDH1%2F2+mutations&amp;author=Lin&amp;publication_year=2013" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref18"><span class="order">18.
            </span><a name="pone.0100206-Lin3" id="pone.0100206-Lin3" class="link-target"></a>Lin CC, Hou HA, Chou WC, Kuo YY, Liu CY, et al. (2013) IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. Am J Hematol. <ul class="reflinks"><li><a href="#" data-author="Lin" data-cit="LinCC%2C%20HouHA%2C%20ChouWC%2C%20KuoYY%2C%20LiuCY%2C%20et%20al.%20%282013%29%20IDH%20mutations%20are%20closely%20associated%20with%20mutations%20of%20DNMT3A%2C%20ASXL1%20and%20SRSF2%20in%20patients%20with%20myelodysplastic%20syndromes%20and%20are%20stable%20during%20disease%20evolution.%20Am%20J%20Hematol." data-title="IDH%20mutations%20are%20closely%20associated%20with%20mutations%20of%20DNMT3A%2C%20ASXL1%20and%20SRSF2%20in%20patients%20with%20myelodysplastic%20syndromes%20and%20are%20stable%20during%20disease%20evolution" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Lin%5Bauthor%5D+AND+IDH+mutations+are+closely+associated+with+mutations+of+DNMT3A%2C+ASXL1+and+SRSF2+in+patients+with+myelodysplastic+syndromes+and+are+stable+during+disease+evolution" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=IDH+mutations+are+closely+associated+with+mutations+of+DNMT3A%2C+ASXL1+and+SRSF2+in+patients+with+myelodysplastic+syndromes+and+are+stable+during+disease+evolution&amp;author=Lin&amp;publication_year=2013" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref19"><span class="order">19.
            </span><a name="pone.0100206-Tierney1" id="pone.0100206-Tierney1" class="link-target"></a>Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16. <ul class="reflinks"><li><a href="#" data-author="Tierney" data-cit="TierneyJF%2C%20StewartLA%2C%20GhersiD%2C%20BurdettS%2C%20SydesMR%20%282007%29%20Practical%20methods%20for%20incorporating%20summary%20time-to-event%20data%20into%20meta-analysis.%20Trials%208%3A%2016." data-title="Practical%20methods%20for%20incorporating%20summary%20time-to-event%20data%20into%20meta-analysis" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Tierney%5Bauthor%5D+AND+Practical+methods+for+incorporating+summary+time-to-event+data+into+meta-analysis" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Practical+methods+for+incorporating+summary+time-to-event+data+into+meta-analysis&amp;author=Tierney&amp;publication_year=2007" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref20"><span class="order">20.
            </span><a name="pone.0100206-Tong1" id="pone.0100206-Tong1" class="link-target"></a>Tong H, Hu C, Yin X, Yu M, Yang J, et al. (2013) A Meta-Analysis of the Relationship between Cigarette Smoking and Incidence of Myelodysplastic Syndromes. PLoS One 8: e67537. <ul class="reflinks"><li><a href="#" data-author="Tong" data-cit="TongH%2C%20HuC%2C%20YinX%2C%20YuM%2C%20YangJ%2C%20et%20al.%20%282013%29%20A%20Meta-Analysis%20of%20the%20Relationship%20between%20Cigarette%20Smoking%20and%20Incidence%20of%20Myelodysplastic%20Syndromes.%20PLoS%20One%208%3A%20e67537." data-title="A%20Meta-Analysis%20of%20the%20Relationship%20between%20Cigarette%20Smoking%20and%20Incidence%20of%20Myelodysplastic%20Syndromes" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Tong%5Bauthor%5D+AND+A+Meta-Analysis+of+the+Relationship+between+Cigarette+Smoking+and+Incidence+of+Myelodysplastic+Syndromes" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=A+Meta-Analysis+of+the+Relationship+between+Cigarette+Smoking+and+Incidence+of+Myelodysplastic+Syndromes&amp;author=Tong&amp;publication_year=2013" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref21"><span class="order">21.
            </span><a name="pone.0100206-Begg1" id="pone.0100206-Begg1" class="link-target"></a>Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088–1101. <ul class="reflinks"><li><a href="#" data-author="Begg" data-cit="BeggCB%2C%20MazumdarM%20%281994%29%20Operating%20characteristics%20of%20a%20rank%20correlation%20test%20for%20publication%20bias.%20Biometrics%2050%3A%201088%E2%80%931101." data-title="Operating%20characteristics%20of%20a%20rank%20correlation%20test%20for%20publication%20bias" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Begg%5Bauthor%5D+AND+Operating+characteristics+of+a+rank+correlation+test+for+publication+bias" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Operating+characteristics+of+a+rank+correlation+test+for+publication+bias&amp;author=Begg&amp;publication_year=1994" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref22"><span class="order">22.
            </span><a name="pone.0100206-Egger1" id="pone.0100206-Egger1" class="link-target"></a>Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634. <ul class="reflinks"><li><a href="#" data-author="Egger" data-cit="EggerM%2C%20Davey%20SmithG%2C%20SchneiderM%2C%20MinderC%20%281997%29%20Bias%20in%20meta-analysis%20detected%20by%20a%20simple%2C%20graphical%20test.%20BMJ%20315%3A%20629%E2%80%93634." data-title="Bias%20in%20meta-analysis%20detected%20by%20a%20simple%2C%20graphical%20test" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Egger%5Bauthor%5D+AND+Bias+in+meta-analysis+detected+by+a+simple%2C+graphical+test" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Bias+in+meta-analysis+detected+by+a+simple%2C+graphical+test&amp;author=Egger&amp;publication_year=1997" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref23"><span class="order">23.
            </span><a name="pone.0100206-Bennett1" id="pone.0100206-Bennett1" class="link-target"></a>Bennett JM (2000) World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72: 131–133. <ul class="reflinks"><li><a href="#" data-author="Bennett" data-cit="BennettJM%20%282000%29%20World%20Health%20Organization%20classification%20of%20the%20acute%20leukemias%20and%20myelodysplastic%20syndrome.%20Int%20J%20Hematol%2072%3A%20131%E2%80%93133." data-title="World%20Health%20Organization%20classification%20of%20the%20acute%20leukemias%20and%20myelodysplastic%20syndrome" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Bennett%5Bauthor%5D+AND+World+Health+Organization+classification+of+the+acute+leukemias+and+myelodysplastic+syndrome" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=World+Health+Organization+classification+of+the+acute+leukemias+and+myelodysplastic+syndrome&amp;author=Bennett&amp;publication_year=2000" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref24"><span class="order">24.
            </span><a name="pone.0100206-Bennett2" id="pone.0100206-Bennett2" class="link-target"></a>Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, et al. (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189–199. <ul class="reflinks"><li><a href="#" data-author="Bennett" data-cit="BennettJM%2C%20CatovskyD%2C%20DanielMT%2C%20FlandrinG%2C%20GaltonDA%2C%20et%20al.%20%281982%29%20Proposals%20for%20the%20classification%20of%20the%20myelodysplastic%20syndromes.%20Br%20J%20Haematol%2051%3A%20189%E2%80%93199." data-title="Proposals%20for%20the%20classification%20of%20the%20myelodysplastic%20syndromes" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Bennett%5Bauthor%5D+AND+Proposals+for+the+classification+of+the+myelodysplastic+syndromes" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Proposals+for+the+classification+of+the+myelodysplastic+syndromes&amp;author=Bennett&amp;publication_year=1982" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref25"><span class="order">25.
            </span><a name="pone.0100206-Tothova1" id="pone.0100206-Tothova1" class="link-target"></a>Tothova Z, Steensma DP, Ebert BL (2013) New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice. Clin Cancer Res 19: 1637–1643. <ul class="reflinks"><li><a href="#" data-author="Tothova" data-cit="TothovaZ%2C%20SteensmaDP%2C%20EbertBL%20%282013%29%20New%20strategies%20in%20myelodysplastic%20syndromes%3A%20application%20of%20molecular%20diagnostics%20to%20clinical%20practice.%20Clin%20Cancer%20Res%2019%3A%201637%E2%80%931643." data-title="New%20strategies%20in%20myelodysplastic%20syndromes%3A%20application%20of%20molecular%20diagnostics%20to%20clinical%20practice" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Tothova%5Bauthor%5D+AND+New+strategies+in+myelodysplastic+syndromes%3A+application+of+molecular+diagnostics+to+clinical+practice" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=New+strategies+in+myelodysplastic+syndromes%3A+application+of+molecular+diagnostics+to+clinical+practice&amp;author=Tothova&amp;publication_year=2013" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref26"><span class="order">26.
            </span><a name="pone.0100206-Muto1" id="pone.0100206-Muto1" class="link-target"></a>Muto T, Sashida G, Oshima M, Wendt GR, Mochizuki-Kashio M, et al. (2013) Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med 210: 2627–2639. <ul class="reflinks"><li><a href="#" data-author="Muto" data-cit="MutoT%2C%20SashidaG%2C%20OshimaM%2C%20WendtGR%2C%20Mochizuki-KashioM%2C%20et%20al.%20%282013%29%20Concurrent%20loss%20of%20Ezh2%20and%20Tet2%20cooperates%20in%20the%20pathogenesis%20of%20myelodysplastic%20disorders.%20J%20Exp%20Med%20210%3A%202627%E2%80%932639." data-title="Concurrent%20loss%20of%20Ezh2%20and%20Tet2%20cooperates%20in%20the%20pathogenesis%20of%20myelodysplastic%20disorders" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Muto%5Bauthor%5D+AND+Concurrent+loss+of+Ezh2+and+Tet2+cooperates+in+the+pathogenesis+of+myelodysplastic+disorders" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Concurrent+loss+of+Ezh2+and+Tet2+cooperates+in+the+pathogenesis+of+myelodysplastic+disorders&amp;author=Muto&amp;publication_year=2013" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref27"><span class="order">27.
            </span><a name="pone.0100206-Krell1" id="pone.0100206-Krell1" class="link-target"></a>Krell D, Assoku M, Galloway M, Mulholland P, Tomlinson I, et al. (2011) Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. PLoS One 6: e19868. <ul class="reflinks"><li><a href="#" data-author="Krell" data-cit="KrellD%2C%20AssokuM%2C%20GallowayM%2C%20MulhollandP%2C%20TomlinsonI%2C%20et%20al.%20%282011%29%20Screen%20for%20IDH1%2C%20IDH2%2C%20IDH3%2C%20D2HGDH%20and%20L2HGDH%20mutations%20in%20glioblastoma.%20PLoS%20One%206%3A%20e19868." data-title="Screen%20for%20IDH1%2C%20IDH2%2C%20IDH3%2C%20D2HGDH%20and%20L2HGDH%20mutations%20in%20glioblastoma" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Krell%5Bauthor%5D+AND+Screen+for+IDH1%2C+IDH2%2C+IDH3%2C+D2HGDH+and+L2HGDH+mutations+in+glioblastoma" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Screen+for+IDH1%2C+IDH2%2C+IDH3%2C+D2HGDH+and+L2HGDH+mutations+in+glioblastoma&amp;author=Krell&amp;publication_year=2011" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref28"><span class="order">28.
            </span><a name="pone.0100206-Jin1" id="pone.0100206-Jin1" class="link-target"></a>Jin G, Reitman ZJ, Spasojevic I, Batinic-Haberle I, Yang J, et al. (2011) 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One 6: e16812. <ul class="reflinks"><li><a href="#" data-author="Jin" data-cit="JinG%2C%20ReitmanZJ%2C%20SpasojevicI%2C%20Batinic-HaberleI%2C%20YangJ%2C%20et%20al.%20%282011%29%202-hydroxyglutarate%20production%2C%20but%20not%20dominant%20negative%20function%2C%20is%20conferred%20by%20glioma-derived%20NADP-dependent%20isocitrate%20dehydrogenase%20mutations.%20PLoS%20One%206%3A%20e16812." data-title="2-hydroxyglutarate%20production%2C%20but%20not%20dominant%20negative%20function%2C%20is%20conferred%20by%20glioma-derived%20NADP-dependent%20isocitrate%20dehydrogenase%20mutations" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Jin%5Bauthor%5D+AND+2-hydroxyglutarate+production%2C+but+not+dominant+negative+function%2C+is+conferred+by+glioma-derived+NADP-dependent+isocitrate+dehydrogenase+mutations" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=2-hydroxyglutarate+production%2C+but+not+dominant+negative+function%2C+is+conferred+by+glioma-derived+NADP-dependent+isocitrate+dehydrogenase+mutations&amp;author=Jin&amp;publication_year=2011" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref29"><span class="order">29.
            </span><a name="pone.0100206-Sjoblom1" id="pone.0100206-Sjoblom1" class="link-target"></a>Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268–274. <ul class="reflinks"><li><a href="#" data-author="Sjoblom" data-cit="SjoblomT%2C%20JonesS%2C%20WoodLD%2C%20ParsonsDW%2C%20LinJ%2C%20et%20al.%20%282006%29%20The%20consensus%20coding%20sequences%20of%20human%20breast%20and%20colorectal%20cancers.%20Science%20314%3A%20268%E2%80%93274." data-title="The%20consensus%20coding%20sequences%20of%20human%20breast%20and%20colorectal%20cancers" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Sjoblom%5Bauthor%5D+AND+The+consensus+coding+sequences+of+human+breast+and+colorectal+cancers" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=The+consensus+coding+sequences+of+human+breast+and+colorectal+cancers&amp;author=Sjoblom&amp;publication_year=2006" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref30"><span class="order">30.
            </span><a name="pone.0100206-Yoshida1" id="pone.0100206-Yoshida1" class="link-target"></a>Yoshida K, Sanada M, Kato M, Kawahata R, Matsubara A, et al. (2011) A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders. Leukemia 25: 184–186. <ul class="reflinks"><li><a href="#" data-author="Yoshida" data-cit="YoshidaK%2C%20SanadaM%2C%20KatoM%2C%20KawahataR%2C%20MatsubaraA%2C%20et%20al.%20%282011%29%20A%20nonsense%20mutation%20of%20IDH1%20in%20myelodysplastic%20syndromes%20and%20related%20disorders.%20Leukemia%2025%3A%20184%E2%80%93186." data-title="A%20nonsense%20mutation%20of%20IDH1%20in%20myelodysplastic%20syndromes%20and%20related%20disorders" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Yoshida%5Bauthor%5D+AND+A+nonsense+mutation+of+IDH1+in+myelodysplastic+syndromes+and+related+disorders" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=A+nonsense+mutation+of+IDH1+in+myelodysplastic+syndromes+and+related+disorders&amp;author=Yoshida&amp;publication_year=2011" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref31"><span class="order">31.
            </span><a name="pone.0100206-Rocquain1" id="pone.0100206-Rocquain1" class="link-target"></a>Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, et al. (2010) Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 10: 401. <ul class="reflinks"><li><a href="#" data-author="Rocquain" data-cit="RocquainJ%2C%20CarbucciaN%2C%20TrouplinV%2C%20RaynaudS%2C%20MuratiA%2C%20et%20al.%20%282010%29%20Combined%20mutations%20of%20ASXL1%2C%20CBL%2C%20FLT3%2C%20IDH1%2C%20IDH2%2C%20JAK2%2C%20KRAS%2C%20NPM1%2C%20NRAS%2C%20RUNX1%2C%20TET2%20and%20WT1%20genes%20in%20myelodysplastic%20syndromes%20and%20acute%20myeloid%20leukemias.%20BMC%20Cancer%2010%3A%20401." data-title="Combined%20mutations%20of%20ASXL1%2C%20CBL%2C%20FLT3%2C%20IDH1%2C%20IDH2%2C%20JAK2%2C%20KRAS%2C%20NPM1%2C%20NRAS%2C%20RUNX1%2C%20TET2%20and%20WT1%20genes%20in%20myelodysplastic%20syndromes%20and%20acute%20myeloid%20leukemias" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Rocquain%5Bauthor%5D+AND+Combined+mutations+of+ASXL1%2C+CBL%2C+FLT3%2C+IDH1%2C+IDH2%2C+JAK2%2C+KRAS%2C+NPM1%2C+NRAS%2C+RUNX1%2C+TET2+and+WT1+genes+in+myelodysplastic+syndromes+and+acute+myeloid+leukemias" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Combined+mutations+of+ASXL1%2C+CBL%2C+FLT3%2C+IDH1%2C+IDH2%2C+JAK2%2C+KRAS%2C+NPM1%2C+NRAS%2C+RUNX1%2C+TET2+and+WT1+genes+in+myelodysplastic+syndromes+and+acute+myeloid+leukemias&amp;author=Rocquain&amp;publication_year=2010" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref32"><span class="order">32.
            </span><a name="pone.0100206-Kosmider1" id="pone.0100206-Kosmider1" class="link-target"></a>Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, et al. (2010) Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 24: 1094–1096. <ul class="reflinks"><li><a href="#" data-author="Kosmider" data-cit="KosmiderO%2C%20Gelsi-BoyerV%2C%20SlamaL%2C%20DreyfusF%2C%20Beyne-RauzyO%2C%20et%20al.%20%282010%29%20Mutations%20of%20IDH1%20and%20IDH2%20genes%20in%20early%20and%20accelerated%20phases%20of%20myelodysplastic%20syndromes%20and%20MDS%2Fmyeloproliferative%20neoplasms.%20Leukemia%2024%3A%201094%E2%80%931096." data-title="Mutations%20of%20IDH1%20and%20IDH2%20genes%20in%20early%20and%20accelerated%20phases%20of%20myelodysplastic%20syndromes%20and%20MDS%2Fmyeloproliferative%20neoplasms" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Kosmider%5Bauthor%5D+AND+Mutations+of+IDH1+and+IDH2+genes+in+early+and+accelerated+phases+of+myelodysplastic+syndromes+and+MDS%2Fmyeloproliferative+neoplasms" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Mutations+of+IDH1+and+IDH2+genes+in+early+and+accelerated+phases+of+myelodysplastic+syndromes+and+MDS%2Fmyeloproliferative+neoplasms&amp;author=Kosmider&amp;publication_year=2010" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref33"><span class="order">33.
            </span><a name="pone.0100206-Abbas1" id="pone.0100206-Abbas1" class="link-target"></a>Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, et al. (2010) Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 116: 2122–2126. <ul class="reflinks"><li><a href="#" data-author="Abbas" data-cit="AbbasS%2C%20LugthartS%2C%20KavelaarsFG%2C%20SchelenA%2C%20KoendersJE%2C%20et%20al.%20%282010%29%20Acquired%20mutations%20in%20the%20genes%20encoding%20IDH1%20and%20IDH2%20both%20are%20recurrent%20aberrations%20in%20acute%20myeloid%20leukemia%3A%20prevalence%20and%20prognostic%20value.%20Blood%20116%3A%202122%E2%80%932126." data-title="Acquired%20mutations%20in%20the%20genes%20encoding%20IDH1%20and%20IDH2%20both%20are%20recurrent%20aberrations%20in%20acute%20myeloid%20leukemia%3A%20prevalence%20and%20prognostic%20value" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Abbas%5Bauthor%5D+AND+Acquired+mutations+in+the+genes+encoding+IDH1+and+IDH2+both+are+recurrent+aberrations+in+acute+myeloid+leukemia%3A+prevalence+and+prognostic+value" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Acquired+mutations+in+the+genes+encoding+IDH1+and+IDH2+both+are+recurrent+aberrations+in+acute+myeloid+leukemia%3A+prevalence+and+prognostic+value&amp;author=Abbas&amp;publication_year=2010" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref34"><span class="order">34.
            </span><a name="pone.0100206-Pardanani1" id="pone.0100206-Pardanani1" class="link-target"></a>Pardanani A, Lasho TL, Finke CM, Mai M, McClure RF, et al. (2010) IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 24: 1146–1151. <ul class="reflinks"><li><a href="#" data-author="Pardanani" data-cit="PardananiA%2C%20LashoTL%2C%20FinkeCM%2C%20MaiM%2C%20McClureRF%2C%20et%20al.%20%282010%29%20IDH1%20and%20IDH2%20mutation%20analysis%20in%20chronic-%20and%20blast-phase%20myeloproliferative%20neoplasms.%20Leukemia%2024%3A%201146%E2%80%931151." data-title="IDH1%20and%20IDH2%20mutation%20analysis%20in%20chronic-%20and%20blast-phase%20myeloproliferative%20neoplasms" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Pardanani%5Bauthor%5D+AND+IDH1+and+IDH2+mutation+analysis+in+chronic-+and+blast-phase+myeloproliferative+neoplasms" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=IDH1+and+IDH2+mutation+analysis+in+chronic-+and+blast-phase+myeloproliferative+neoplasms&amp;author=Pardanani&amp;publication_year=2010" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref35"><span class="order">35.
            </span><a name="pone.0100206-Tefferi1" id="pone.0100206-Tefferi1" class="link-target"></a>Tefferi A, Jimma T, Sulai NH, Lasho TL, Finke CM, et al. (2012) IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 26: 475–480. <ul class="reflinks"><li><a href="#" data-author="Tefferi" data-cit="TefferiA%2C%20JimmaT%2C%20SulaiNH%2C%20LashoTL%2C%20FinkeCM%2C%20et%20al.%20%282012%29%20IDH%20mutations%20in%20primary%20myelofibrosis%20predict%20leukemic%20transformation%20and%20shortened%20survival%3A%20clinical%20evidence%20for%20leukemogenic%20collaboration%20with%20JAK2V617F.%20Leukemia%2026%3A%20475%E2%80%93480." data-title="IDH%20mutations%20in%20primary%20myelofibrosis%20predict%20leukemic%20transformation%20and%20shortened%20survival%3A%20clinical%20evidence%20for%20leukemogenic%20collaboration%20with%20JAK2V617F" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Tefferi%5Bauthor%5D+AND+IDH+mutations+in+primary+myelofibrosis+predict+leukemic+transformation+and+shortened+survival%3A+clinical+evidence+for+leukemogenic+collaboration+with+JAK2V617F" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=IDH+mutations+in+primary+myelofibrosis+predict+leukemic+transformation+and+shortened+survival%3A+clinical+evidence+for+leukemogenic+collaboration+with+JAK2V617F&amp;author=Tefferi&amp;publication_year=2012" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref36"><span class="order">36.
            </span><a name="pone.0100206-Chou1" id="pone.0100206-Chou1" class="link-target"></a>Chou WC, Lei WC, Ko BS, Hou HA, Chen CY, et al. (2011) The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 25: 246–253. <ul class="reflinks"><li><a href="#" data-author="Chou" data-cit="ChouWC%2C%20LeiWC%2C%20KoBS%2C%20HouHA%2C%20ChenCY%2C%20et%20al.%20%282011%29%20The%20prognostic%20impact%20and%20stability%20of%20Isocitrate%20dehydrogenase%202%20mutation%20in%20adult%20patients%20with%20acute%20myeloid%20leukemia.%20Leukemia%2025%3A%20246%E2%80%93253." data-title="The%20prognostic%20impact%20and%20stability%20of%20Isocitrate%20dehydrogenase%202%20mutation%20in%20adult%20patients%20with%20acute%20myeloid%20leukemia" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Chou%5Bauthor%5D+AND+The+prognostic+impact+and+stability+of+Isocitrate+dehydrogenase+2+mutation+in+adult+patients+with+acute+myeloid+leukemia" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=The+prognostic+impact+and+stability+of+Isocitrate+dehydrogenase+2+mutation+in+adult+patients+with+acute+myeloid+leukemia&amp;author=Chou&amp;publication_year=2011" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref37"><span class="order">37.
            </span><a name="pone.0100206-Chou2" id="pone.0100206-Chou2" class="link-target"></a>Chou WC, Hou HA, Chen CY, Tang JL, Yao M, et al. (2010) Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 115: 2749–2754. <ul class="reflinks"><li><a href="#" data-author="Chou" data-cit="ChouWC%2C%20HouHA%2C%20ChenCY%2C%20TangJL%2C%20YaoM%2C%20et%20al.%20%282010%29%20Distinct%20clinical%20and%20biologic%20characteristics%20in%20adult%20acute%20myeloid%20leukemia%20bearing%20the%20isocitrate%20dehydrogenase%201%20mutation.%20Blood%20115%3A%202749%E2%80%932754." data-title="Distinct%20clinical%20and%20biologic%20characteristics%20in%20adult%20acute%20myeloid%20leukemia%20bearing%20the%20isocitrate%20dehydrogenase%201%20mutation" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Chou%5Bauthor%5D+AND+Distinct+clinical+and+biologic+characteristics+in+adult+acute+myeloid+leukemia+bearing+the+isocitrate+dehydrogenase+1+mutation" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Distinct+clinical+and+biologic+characteristics+in+adult+acute+myeloid+leukemia+bearing+the+isocitrate+dehydrogenase+1+mutation&amp;author=Chou&amp;publication_year=2010" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref38"><span class="order">38.
            </span><a name="pone.0100206-Caramazza1" id="pone.0100206-Caramazza1" class="link-target"></a>Caramazza D, Lasho TL, Finke CM, Gangat N, Dingli D, et al. (2010) IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 24: 2120–2122. <ul class="reflinks"><li><a href="#" data-author="Caramazza" data-cit="CaramazzaD%2C%20LashoTL%2C%20FinkeCM%2C%20GangatN%2C%20DingliD%2C%20et%20al.%20%282010%29%20IDH%20mutations%20and%20trisomy%208%20in%20myelodysplastic%20syndromes%20and%20acute%20myeloid%20leukemia.%20Leukemia%2024%3A%202120%E2%80%932122." data-title="IDH%20mutations%20and%20trisomy%208%20in%20myelodysplastic%20syndromes%20and%20acute%20myeloid%20leukemia" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Caramazza%5Bauthor%5D+AND+IDH+mutations+and+trisomy+8+in+myelodysplastic+syndromes+and+acute+myeloid+leukemia" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=IDH+mutations+and+trisomy+8+in+myelodysplastic+syndromes+and+acute+myeloid+leukemia&amp;author=Caramazza&amp;publication_year=2010" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref39"><span class="order">39.
            </span><a name="pone.0100206-Fathi1" id="pone.0100206-Fathi1" class="link-target"></a>Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, et al. (2012) Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood 120: 4649–4652. <ul class="reflinks"><li><a href="#" data-author="Fathi" data-cit="FathiAT%2C%20SadrzadehH%2C%20BorgerDR%2C%20BallenKK%2C%20AmreinPC%2C%20et%20al.%20%282012%29%20Prospective%20serial%20evaluation%20of%202-hydroxyglutarate%2C%20during%20treatment%20of%20newly%20diagnosed%20acute%20myeloid%20leukemia%2C%20to%20assess%20disease%20activity%20and%20therapeutic%20response.%20Blood%20120%3A%204649%E2%80%934652." data-title="Prospective%20serial%20evaluation%20of%202-hydroxyglutarate%2C%20during%20treatment%20of%20newly%20diagnosed%20acute%20myeloid%20leukemia%2C%20to%20assess%20disease%20activity%20and%20therapeutic%20response" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Fathi%5Bauthor%5D+AND+Prospective+serial+evaluation+of+2-hydroxyglutarate%2C+during+treatment+of+newly+diagnosed+acute+myeloid+leukemia%2C+to+assess+disease+activity+and+therapeutic+response" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Prospective+serial+evaluation+of+2-hydroxyglutarate%2C+during+treatment+of+newly+diagnosed+acute+myeloid+leukemia%2C+to+assess+disease+activity+and+therapeutic+response&amp;author=Fathi&amp;publication_year=2012" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref40"><span class="order">40.
            </span><a name="pone.0100206-Dinardo1" id="pone.0100206-Dinardo1" class="link-target"></a>Dinardo CD, Propert KJ, Loren AW, Paietta E, Sun Z, et al. (2013) Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 121: 4917–4924. <ul class="reflinks"><li><a href="#" data-author="Dinardo" data-cit="DinardoCD%2C%20PropertKJ%2C%20LorenAW%2C%20PaiettaE%2C%20SunZ%2C%20et%20al.%20%282013%29%20Serum%202-hydroxyglutarate%20levels%20predict%20isocitrate%20dehydrogenase%20mutations%20and%20clinical%20outcome%20in%20acute%20myeloid%20leukemia.%20Blood%20121%3A%204917%E2%80%934924." data-title="Serum%202-hydroxyglutarate%20levels%20predict%20isocitrate%20dehydrogenase%20mutations%20and%20clinical%20outcome%20in%20acute%20myeloid%20leukemia" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Dinardo%5Bauthor%5D+AND+Serum+2-hydroxyglutarate+levels+predict+isocitrate+dehydrogenase+mutations+and+clinical+outcome+in+acute+myeloid+leukemia" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Serum+2-hydroxyglutarate+levels+predict+isocitrate+dehydrogenase+mutations+and+clinical+outcome+in+acute+myeloid+leukemia&amp;author=Dinardo&amp;publication_year=2013" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref41"><span class="order">41.
            </span><a name="pone.0100206-Steensma1" id="pone.0100206-Steensma1" class="link-target"></a>Steensma DP (2006) Are myelodysplastic syndromes “cancer”? Unexpected adverse consequences of linguistic ambiguity. Leuk Res 30: 1227–1233. <ul class="reflinks"><li><a href="#" data-author="Steensma" data-cit="SteensmaDP%20%282006%29%20Are%20myelodysplastic%20syndromes%20%E2%80%9Ccancer%E2%80%9D%3F%20Unexpected%20adverse%20consequences%20of%20linguistic%20ambiguity.%20Leuk%20Res%2030%3A%201227%E2%80%931233." data-title="Are%20myelodysplastic%20syndromes%20%E2%80%9Ccancer%E2%80%9D%3F%20Unexpected%20adverse%20consequences%20of%20linguistic%20ambiguity" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Steensma%5Bauthor%5D+AND+Are+myelodysplastic+syndromes+%E2%80%9Ccancer%E2%80%9D%3F+Unexpected+adverse+consequences+of+linguistic+ambiguity" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Are+myelodysplastic+syndromes+%E2%80%9Ccancer%E2%80%9D%3F+Unexpected+adverse+consequences+of+linguistic+ambiguity&amp;author=Steensma&amp;publication_year=2006" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref42"><span class="order">42.
            </span><a name="pone.0100206-Khan1" id="pone.0100206-Khan1" class="link-target"></a>Khan H, Vale C, Bhagat T, Verma A (2013) Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes. Semin Hematol 50: 16–37. <ul class="reflinks"><li><a href="#" data-author="Khan" data-cit="KhanH%2C%20ValeC%2C%20BhagatT%2C%20VermaA%20%282013%29%20Role%20of%20DNA%20methylation%20in%20the%20pathogenesis%20and%20treatment%20of%20myelodysplastic%20syndromes.%20Semin%20Hematol%2050%3A%2016%E2%80%9337." data-title="Role%20of%20DNA%20methylation%20in%20the%20pathogenesis%20and%20treatment%20of%20myelodysplastic%20syndromes" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Khan%5Bauthor%5D+AND+Role+of+DNA+methylation+in+the+pathogenesis+and+treatment+of+myelodysplastic+syndromes" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Role+of+DNA+methylation+in+the+pathogenesis+and+treatment+of+myelodysplastic+syndromes&amp;author=Khan&amp;publication_year=2013" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref43"><span class="order">43.
            </span><a name="pone.0100206-Dang1" id="pone.0100206-Dang1" class="link-target"></a>Dang L, White DW, Gross S, Bennett BD, Bittinger MA, et al. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739–744. <ul class="reflinks"><li><a href="#" data-author="Dang" data-cit="DangL%2C%20WhiteDW%2C%20GrossS%2C%20BennettBD%2C%20BittingerMA%2C%20et%20al.%20%282009%29%20Cancer-associated%20IDH1%20mutations%20produce%202-hydroxyglutarate.%20Nature%20462%3A%20739%E2%80%93744." data-title="Cancer-associated%20IDH1%20mutations%20produce%202-hydroxyglutarate" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Dang%5Bauthor%5D+AND+Cancer-associated+IDH1+mutations+produce+2-hydroxyglutarate" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Cancer-associated+IDH1+mutations+produce+2-hydroxyglutarate&amp;author=Dang&amp;publication_year=2009" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref44"><span class="order">44.
            </span><a name="pone.0100206-Figueroa1" id="pone.0100206-Figueroa1" class="link-target"></a>Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, et al. (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553–567. <ul class="reflinks"><li><a href="#" data-author="Figueroa" data-cit="FigueroaME%2C%20Abdel-WahabO%2C%20LuC%2C%20WardPS%2C%20PatelJ%2C%20et%20al.%20%282010%29%20Leukemic%20IDH1%20and%20IDH2%20mutations%20result%20in%20a%20hypermethylation%20phenotype%2C%20disrupt%20TET2%20function%2C%20and%20impair%20hematopoietic%20differentiation.%20Cancer%20Cell%2018%3A%20553%E2%80%93567." data-title="Leukemic%20IDH1%20and%20IDH2%20mutations%20result%20in%20a%20hypermethylation%20phenotype%2C%20disrupt%20TET2%20function%2C%20and%20impair%20hematopoietic%20differentiation" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Figueroa%5Bauthor%5D+AND+Leukemic+IDH1+and+IDH2+mutations+result+in+a+hypermethylation+phenotype%2C+disrupt+TET2+function%2C+and+impair+hematopoietic+differentiation" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Leukemic+IDH1+and+IDH2+mutations+result+in+a+hypermethylation+phenotype%2C+disrupt+TET2+function%2C+and+impair+hematopoietic+differentiation&amp;author=Figueroa&amp;publication_year=2010" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref45"><span class="order">45.
            </span><a name="pone.0100206-Ward1" id="pone.0100206-Ward1" class="link-target"></a>Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, et al. (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17: 225–234. <ul class="reflinks"><li><a href="#" data-author="Ward" data-cit="WardPS%2C%20PatelJ%2C%20WiseDR%2C%20Abdel-WahabO%2C%20BennettBD%2C%20et%20al.%20%282010%29%20The%20common%20feature%20of%20leukemia-associated%20IDH1%20and%20IDH2%20mutations%20is%20a%20neomorphic%20enzyme%20activity%20converting%20alpha-ketoglutarate%20to%202-hydroxyglutarate.%20Cancer%20Cell%2017%3A%20225%E2%80%93234." data-title="The%20common%20feature%20of%20leukemia-associated%20IDH1%20and%20IDH2%20mutations%20is%20a%20neomorphic%20enzyme%20activity%20converting%20alpha-ketoglutarate%20to%202-hydroxyglutarate" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Ward%5Bauthor%5D+AND+The+common+feature+of+leukemia-associated+IDH1+and+IDH2+mutations+is+a+neomorphic+enzyme+activity+converting+alpha-ketoglutarate+to+2-hydroxyglutarate" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=The+common+feature+of+leukemia-associated+IDH1+and+IDH2+mutations+is+a+neomorphic+enzyme+activity+converting+alpha-ketoglutarate+to+2-hydroxyglutarate&amp;author=Ward&amp;publication_year=2010" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref46"><span class="order">46.
            </span><a name="pone.0100206-Zhao1" id="pone.0100206-Zhao1" class="link-target"></a>Zhao S, Lin Y, Xu W, Jiang W, Zha Z, et al. (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324: 261–265. <ul class="reflinks"><li><a href="#" data-author="Zhao" data-cit="ZhaoS%2C%20LinY%2C%20XuW%2C%20JiangW%2C%20ZhaZ%2C%20et%20al.%20%282009%29%20Glioma-derived%20mutations%20in%20IDH1%20dominantly%20inhibit%20IDH1%20catalytic%20activity%20and%20induce%20HIF-1alpha.%20Science%20324%3A%20261%E2%80%93265." data-title="Glioma-derived%20mutations%20in%20IDH1%20dominantly%20inhibit%20IDH1%20catalytic%20activity%20and%20induce%20HIF-1alpha" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Zhao%5Bauthor%5D+AND+Glioma-derived+mutations+in+IDH1+dominantly+inhibit+IDH1+catalytic+activity+and+induce+HIF-1alpha" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Glioma-derived+mutations+in+IDH1+dominantly+inhibit+IDH1+catalytic+activity+and+induce+HIF-1alpha&amp;author=Zhao&amp;publication_year=2009" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref47"><span class="order">47.
            </span><a name="pone.0100206-Tong2" id="pone.0100206-Tong2" class="link-target"></a>Tong H, Hu C, Zhuang Z, Wang L, Jin J (2012) Hypoxia-inducible factor-1alpha expression indicates poor prognosis in myelodysplastic syndromes. Leuk Lymphoma 53: 2412–2418. <ul class="reflinks"><li><a href="#" data-author="Tong" data-cit="TongH%2C%20HuC%2C%20ZhuangZ%2C%20WangL%2C%20JinJ%20%282012%29%20Hypoxia-inducible%20factor-1alpha%20expression%20indicates%20poor%20prognosis%20in%20myelodysplastic%20syndromes.%20Leuk%20Lymphoma%2053%3A%202412%E2%80%932418." data-title="Hypoxia-inducible%20factor-1alpha%20expression%20indicates%20poor%20prognosis%20in%20myelodysplastic%20syndromes" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Tong%5Bauthor%5D+AND+Hypoxia-inducible+factor-1alpha+expression+indicates+poor+prognosis+in+myelodysplastic+syndromes" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Hypoxia-inducible+factor-1alpha+expression+indicates+poor+prognosis+in+myelodysplastic+syndromes&amp;author=Tong&amp;publication_year=2012" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref48"><span class="order">48.
            </span><a name="pone.0100206-Head1" id="pone.0100206-Head1" class="link-target"></a>Head DR, Jacobberger JW, Mosse C, Jagasia M, Dupont W, et al. (2011) Innovative analyses support a role for DNA damage and an aberrant cell cycle in myelodysplastic syndrome pathogenesis. Bone Marrow Res 2011: 950934. <ul class="reflinks"><li><a href="#" data-author="Head" data-cit="HeadDR%2C%20JacobbergerJW%2C%20MosseC%2C%20JagasiaM%2C%20DupontW%2C%20et%20al.%20%282011%29%20Innovative%20analyses%20support%20a%20role%20for%20DNA%20damage%20and%20an%20aberrant%20cell%20cycle%20in%20myelodysplastic%20syndrome%20pathogenesis.%20Bone%20Marrow%20Res%202011%3A%20950934." data-title="Innovative%20analyses%20support%20a%20role%20for%20DNA%20damage%20and%20an%20aberrant%20cell%20cycle%20in%20myelodysplastic%20syndrome%20pathogenesis" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Head%5Bauthor%5D+AND+Innovative+analyses+support+a+role+for+DNA+damage+and+an+aberrant+cell+cycle+in+myelodysplastic+syndrome+pathogenesis" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Innovative+analyses+support+a+role+for+DNA+damage+and+an+aberrant+cell+cycle+in+myelodysplastic+syndrome+pathogenesis&amp;author=Head&amp;publication_year=2011" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref49"><span class="order">49.
            </span><a name="pone.0100206-Grimes1" id="pone.0100206-Grimes1" class="link-target"></a>Grimes DA, Schulz KF (2002) Cohort studies: marching towards outcomes. Lancet 359: 341–345. <ul class="reflinks"><li><a href="#" data-author="Grimes" data-cit="GrimesDA%2C%20SchulzKF%20%282002%29%20Cohort%20studies%3A%20marching%20towards%20outcomes.%20Lancet%20359%3A%20341%E2%80%93345." data-title="Cohort%20studies%3A%20marching%20towards%20outcomes" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Grimes%5Bauthor%5D+AND+Cohort+studies%3A+marching+towards+outcomes" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=Cohort+studies%3A+marching+towards+outcomes&amp;author=Grimes&amp;publication_year=2002" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li><li id="ref50"><span class="order">50.
            </span><a name="pone.0100206-AbdelWahab1" id="pone.0100206-AbdelWahab1" class="link-target"></a>Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, et al. (2012) ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22: 180–193. <ul class="reflinks"><li><a href="#" data-author="Abdel-Wahab" data-cit="Abdel-WahabO%2C%20AdliM%2C%20LaFaveLM%2C%20GaoJ%2C%20HricikT%2C%20et%20al.%20%282012%29%20ASXL1%20mutations%20promote%20myeloid%20transformation%20through%20loss%20of%20PRC2-mediated%20gene%20repression.%20Cancer%20Cell%2022%3A%20180%E2%80%93193." data-title="ASXL1%20mutations%20promote%20myeloid%20transformation%20through%20loss%20of%20PRC2-mediated%20gene%20repression" target="_new" title="Go to article in CrossRef">
                      View Article
                    </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Abdel-Wahab%5Bauthor%5D+AND+ASXL1+mutations+promote+myeloid+transformation+through+loss+of+PRC2-mediated+gene+repression" target="_new" title="Go to article in PubMed">
                      PubMed/NCBI
                    </a></li><li><a href="http://scholar.google.com/scholar_lookup?title=ASXL1+mutations+promote+myeloid+transformation+through+loss+of+PRC2-mediated+gene+repression&amp;author=Abdel-Wahab&amp;publication_year=2012" target="_new" title="Go to article in Google Scholar">
                      Google Scholar
                    </a></li></ul></li></ol></div>



          <div class="ref-tooltip">
             <div class="ref_tooltip-content">

             </div>
          </div>

        </div>
      </div>
    </div>

    </section>
    <aside class="article-aside">


<!--[if IE 9]>
<style>
.dload-xml {margin-top: 38px}
</style>
<![endif]-->
<div class="dload-menu">
  <div class="dload-pdf">
    <a href="/plosone/article/file?id=10.1371/journal.pone.0100206&type=printable"
       id="downloadPdf" target="_blank">Download PDF</a>
  </div>
  <div data-js-tooltip-hover="trigger" class="dload-hover">&nbsp;
    <ul class="dload-xml" data-js-tooltip-hover="target">
      <li><a href="/plosone/article/citation?id=10.1371/journal.pone.0100206"
             id="downloadCitation">Citation</a></li>
      <li><a href="/plosone/article/file?id=10.1371/journal.pone.0100206&type=manuscript"
             id="downloadXml">XML</a>
      </li>
    </ul>

  </div>
</div>

<div class="aside-container">

<div class="print-article" id="printArticle" data-js-tooltip-hover="trigger">

  Print
  <ul class="print-options" data-js-tooltip-hover="target">
    <li>
        <a href="#" onclick="window.print(); return false;" class="preventDefault" id="printBrowser" title="Print
        Article">Print article</a>
    </li>




<li>
<a title="Odyssey Press" href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&amp;page=0&amp;journal=7&amp;doi=10.1371%2Fjournal.pone.0100206&amp;volume=&amp;issue=&amp;title=Prognostic%20Value%20of%20Isocitrate%20Dehydrogenase%20Mutations%20in%20Myelodysplastic%20Syndromes%3A%20A%20Retrospective%20Cohort%20Study%20and%20Meta-Analysis&amp;author_name=Jie%20Jin%2C%20Chao%20Hu%2C%20Mengxia%20Yu%2C%20Feifei%20Chen%2C%20Li%20Ye%2C%20Xiufeng%20Yin%2C%20Zhengping%20Zhuang%2C%20Hongyan%20Tong&amp;start_page=1&amp;end_page=10">EzReprint  </a>
</li>

  </ul>
</div>

<div class="share-article" id="shareArticle" data-js-tooltip-hover="trigger">
  Share
  <ul data-js-tooltip-hover="target" class="share-options">

    <li><a href="http://www.reddit.com/submit?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0100206" id="shareReddit" target="_blank" title="Submit to Reddit"><img src="/plosone/resource/img/icon.reddit.16.png" width="16" height="16" alt="Reddit">Reddit</a></li>

    <li><a href="https://plus.google.com/share?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0100206" id="shareGoogle" target="_blank" title="Share on Google+"><img src="/plosone/resource/img/icon.gplus.16.png" width="16" height="16" alt="Google+">Google+</a></li>

    <li><a href="http://www.stumbleupon.com/submit?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0100206"  id="shareStumble" target="_blank" title="Add to StumbleUpon"><img src="/plosone/resource/img/icon.stumble.16.png" width="16" height="16" alt="StumbleUpon">StumbleUpon</a></li>

    <li><a href="http://www.facebook.com/share.php?u=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0100206&t=Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis" id="shareFacebook" target="_blank" title="Share on Facebook"><img src="/plosone/resource/img/icon.fb.16.png" width="16" height="16" alt="Facebook">Facebook</a></li>



<li><a href="http://www.linkedin.com/shareArticle?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0100206&title=Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis&summary=Checkout this article I found at PLOS"  id="shareLinkedIn" target="_blank" title="Add to LinkedIn"><img src="/plosone/resource/img/icon.linkedin.16.png" width="16" height="16" alt="LinkedIn">LinkedIn</a></li>

<li><a href="http://www.citeulike.org/posturl?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0100206&title=Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis"  id="shareCiteULike" target="_blank" title="Add to CiteULike"><img src="/plosone/resource/img/icon.cul.16.png" width="16" height="16" alt="CiteULike">CiteULike</a></li>

<li><a href="http://www.mendeley.com/import/?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0100206"  id="shareMendeley" target="_blank" title="Add to Mendeley"><img src="/plosone/resource/img/icon.mendeley.16.png" width="16" height="16" alt="Mendeley">Mendeley</a></li>

<li><a href="https://www.pubchase.com/library?add_aid=10.1371/journal.pone.0100206&source=plos"  id="sharePubChase" target="_blank" title="Add to PubChase"><img src="/plosone/resource/img/icon.pc.16.png" width="16" height="16" alt="PubChase">PubChase</a></li>

  <li><a href="http://twitter.com/intent/tweet?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0100206&text=%23PLOSONE%3A%20Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis" target="_blank" title="share on Twitter" id="twitter-share-link"><img src="/plosone/resource/img/icon.twtr.16.png" width="16" height="16" alt="Twitter">Twitter</a></li>

<li><a href="/plosone/article/email?id=10.1371/journal.pone.0100206" id="shareEmail" title="Email this article"><img src="/plosone/resource/img/icon.email.16.png" width="16" height="16" alt="Email">Email</a></li>

  </ul>
</div></div>


 <!-- Crossmark 2.0 widget -->
<script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script>
<a data-target="crossmark"><img width="150" src="http://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_BW_horizontal.svg"></a>
<!-- End Crossmark 2.0 widget -->







<div class="skyscraper-container">
  <div class="title">Advertisement</div>
<!-- DoubleClick Ad Zone -->
  <div class='advertisement' id='div-gpt-ad-1458247671871-1' style='width:160px; height:600px;'>
    <script type='text/javascript'>
      googletag.cmd.push(function() { googletag.display('div-gpt-ad-1458247671871-1'); });
    </script>
  </div>
</div>




<div class="subject-areas-container">
  <h3>Subject Areas <div id="subjInfo">?</div>
    <div id="subjInfoText">
        <p>For more information about PLOS Subject Areas, click
          <a href="/plosone/s/help-using-this-site#loc-subject-areas">here</a>.</p>
      <span class="inline-intro">We want your feedback.</span> Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!


    </div>
  </h3>
  <ul id="subjectList">
      <li>
              <a class="taxo-term" title="Search for articles about Meta-analysis"
                 href="/plosone/search?filterSubjects=Meta-analysis&filterJournals=PLoSONE&q=">Meta-analysis</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Meta-analysis"><p class="taxo-explain">Is the Subject Area <strong>"Meta-analysis"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Prognosis"
                 href="/plosone/search?filterSubjects=Prognosis&filterJournals=PLoSONE&q=">Prognosis</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Prognosis"><p class="taxo-explain">Is the Subject Area <strong>"Prognosis"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Mutation detection"
                 href="/plosone/search?filterSubjects=Mutation+detection&filterJournals=PLoSONE&q=">Mutation detection</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Mutation detection"><p class="taxo-explain">Is the Subject Area <strong>"Mutation detection"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Karyotypes"
                 href="/plosone/search?filterSubjects=Karyotypes&filterJournals=PLoSONE&q=">Karyotypes</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Karyotypes"><p class="taxo-explain">Is the Subject Area <strong>"Karyotypes"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Cancer treatment"
                 href="/plosone/search?filterSubjects=Cancer+treatment&filterJournals=PLoSONE&q=">Cancer treatment</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Cancer treatment"><p class="taxo-explain">Is the Subject Area <strong>"Cancer treatment"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Cytogenetics"
                 href="/plosone/search?filterSubjects=Cytogenetics&filterJournals=PLoSONE&q=">Cytogenetics</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Cytogenetics"><p class="taxo-explain">Is the Subject Area <strong>"Cytogenetics"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Mutation"
                 href="/plosone/search?filterSubjects=Mutation&filterJournals=PLoSONE&q=">Mutation</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Mutation"><p class="taxo-explain">Is the Subject Area <strong>"Mutation"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
      <li>
              <a class="taxo-term" title="Search for articles about Myelodysplastic syndromes"
                 href="/plosone/search?filterSubjects=Myelodysplastic+syndromes&filterJournals=PLoSONE&q=">Myelodysplastic syndromes</a>
        <span class="taxo-flag">&nbsp;</span>
        <div class="taxo-tooltip" data-categoryname="Myelodysplastic syndromes"><p class="taxo-explain">Is the Subject Area <strong>"Myelodysplastic syndromes"</strong> applicable to this article?
          <button id="noFlag" data-action="remove">Yes</button>
          <button id="flagIt" value="flagno" data-action="add">No</button></p>
          <p class="taxo-confirm">Thanks for your feedback.</p>
        </div>
      </li>
  </ul>
</div>
<div id="subjectErrors"></div>


<div class="twitter-container">
  <h3>Archived Tweets</h3>
  <ul id="tweetList">

  </ul>
  <div class="load-more">Load more <span></span></div>
  <div class="view-all"><a href="http://alm.plos.org/works/doi.org/10.1371/journal.pone.0100206?source_id=twitter">View all tweets</a>
  </div>
</div>

<script type="text/template" id="twitterModuleItemTemplate">
  <% _.each(items, function(item) { %>
    <li>
      <div class="tweet-info">
        <a href="http://twitter.com/<%= item.user %>">
          <span class="imgholder">
            <img class="imgLoad" src="<%= item.user_profile_image %>">
          </span>
          <div class="tweetDate"><%= item.created_at %></div>
          <div class="tweetUser">
            <strong><%= item.user_name %></strong>
            <span>@<%= item.user %></span>
          </div>
        </a>
      </div>
      <div class="tweetText">
        <%= item.text %>
      </div>
      <div id="tweetActions">
        <a class="tweet-reply" href="https://twitter.com/intent/tweet?in_reply_to<%= item.id %>&amp;text=@<%= item.user %>">
          <div>&nbsp;</div> Reply
        </a>
        <a class="tweet-retweet" href="https://twitter.com/intent/retweet?tweet_id=<%= item.id %>">
          <div>&nbsp;</div> Retweet
        </a>
        <a class="tweet-favorite" href="https://twitter.com/intent/favorite?tweet_id=<%= item.id %>">
          <div>&nbsp;</div> Favorite
        </a>
      </div>
    </li>
  <% }); %>
</script>

    </aside>
  </div>




</main>

<footer id="pageftr">
  <div class="row">
    <div class="brand-column">

      <img src="/plosone/resource/img/logo-plos-footer.png" alt="PLOS" class="logo-footer"/>
      <p class="nav-special">

&nbsp;
<!--
  Webapp build:  3.3.5 at 20170725 by teamcity, commit: 
  Service build: 2.2.3 at 20170626 by teamcity, commit: 
  Enabled dev features: []
  -->
      </p>

<ul class="nav-aux">
  <li><a href="https://www.plos.org/privacy-policy" id="ftr-privacy">Privacy Policy</a></li>
  <li><a href="https://www.plos.org/terms-of-use" id="ftr-terms">Terms of Use</a></li>
  <li><a href="https://www.plos.org/advertise/" id="ftr-advertise">Advertise</a></li>
  <li><a href="https://www.plos.org/media-inquiries" id="ftr-media">Media Inquiries</a></li>
</ul>
    </div>
    <div class="link-column">

<p class="nav-special"><a href="https://www.plos.org/publications/journals/">Publications</a></p>

<div class="nav">
  <ul>
    <li><a href="/plosbiology/" id="ftr-bio">PLOS Biology</a></li>
    <li><a href="/plosmedicine/" id="ftr-med">PLOS Medicine</a></li>
    <li><a href="/ploscompbiol/" id="ftr-compbio">PLOS Computational Biology</a></li>
    <li><a href="http://currents.plos.org" id="ftr-cur">PLOS Currents</a></li>
    <li><a href="/plosgenetics/" id="ftr-gen">PLOS Genetics</a></li>
    <li><a href="/plospathogens/" id="ftr-path">PLOS Pathogens</a></li>
    <li><a href="/plosone/" id="ftr-one">PLOS ONE</a></li>
    <li><a href="/plosntds/" id="ftr-ntds">PLOS Neglected Tropical Diseases</a></li>
  </ul>
</div>
    </div>
    <div class="link-column">

<div class="nav nav-special">
  <p><a href="https://www.plos.org" id="ftr-home">plos.org</a></p>

  <p><a href="http://blogs.plos.org" id="ftr-blog">Blogs</a></p>

  <p><a href="http://collections.plos.org" id="ftr-collections">Collections</a></p>

  <p><a href="/plosone/feedback" id="ftr-feedback">Send us feedback</a></p>
  <p><a href="/plosone/s/help-using-this-site"
        id="ftr-help">Help using this site</a></p>
  <p><a href="/plosone/lockss-manifest" id="ftr-lockss">LOCKSS</a></p>

<p class="footer-non-profit-statement">PLOS is a nonprofit 501(c)(3) corporation, #C2354500, and is based in San Francisco, California, US</p></div>    </div>
  </div>


</footer>




<script type="text/javascript">
  var ArticleData = {
    doi: '10.1371/journal.pone.0100206',
    title: '<article-title xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Prognostic Value of <italic>Isocitrate Dehydrogenase<\/italic> Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis<\/article-title>',
    date: 'Jun 17, 2014'
  };
</script>







<script type="text/javascript" async src="//platform.twitter.com/widgets.js"></script>





<!-- This file should be loaded before the renderJs, to avoid conflicts with the FigShare, that implements the MathJax also. -->

<!--  mathjax configuration options  -->
<!-- more can be found at http://docs.mathjax.org/en/latest/ -->
<script type="text/x-mathjax-config">
MathJax.Hub.Config({
  "HTML-CSS": {
    scale: 100,
    availableFonts: ["STIX","TeX"],
    preferredFont: "STIX",
    webFont: "STIX-Web",
    linebreaks: { automatic: false }
  },
  jax: ["input/MathML", "output/HTML-CSS"]
});
</script>

<script type="text/javascript" src="https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=MML_HTMLorMML"></script>

<script src="/plosone/resource/compiled/asset_V4KEKJMAKU34D33A4HSQGT4JUZQJDCQS.js"></script>
<div class="reveal-modal-bg"></div>
</body>
</html>
